<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral and sublingual immunotherapy for egg allergy - Romantsik, O - 2018 | Cochrane Library</title> <meta content="Oral and sublingual immunotherapy for egg allergy - Romantsik, O - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010638.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral and sublingual immunotherapy for egg allergy - Romantsik, O - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010638.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010638.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Oral and sublingual immunotherapy for egg allergy" name="citation_title"/> <meta content="Olga Romantsik" name="citation_author"/> <meta content="Lund University, Skåne University Hospital" name="citation_author_institution"/> <meta content="olga.romantsik@gmail.com" name="citation_author_email"/> <meta content="Maria Angela Tosca" name="citation_author"/> <meta content="Istituto Giannina Gaslini" name="citation_author_institution"/> <meta content="Simona Zappettini" name="citation_author"/> <meta content="Regional Center of Pharmacovigilance of Liguria Region, A.Li.Sa." name="citation_author_institution"/> <meta content="Maria Grazia Calevo" name="citation_author"/> <meta content="Istituto Giannina Gaslini" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD010638.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/04/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010638.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010638.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010638.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Desensitization, Immunologic [adverse effects, *methods]; Egg Hypersensitivity [*therapy]; Egg Proteins, Dietary [*administration &amp; dosage, immunology]; Epinephrine [therapeutic use]; Immunoglobulin E [immunology]; Randomized Controlled Trials as Topic; Sublingual Immunotherapy [adverse effects, methods]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010638.pub3&amp;doi=10.1002/14651858.CD010638.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="mvgXlmVk";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010638\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010638\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","pt","ms","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010638.pub3",title:"Oral and sublingual immunotherapy for egg allergy",firstPublishedDate:"Apr 20, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Tobacco Addiction Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010638.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010638.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010638.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010638.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010638.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010638.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010638.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010638.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010638.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010638.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8312 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010638.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-sec-0087"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/appendices#CD010638-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/table_n/CD010638StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/table_n/CD010638StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral and sublingual immunotherapy for egg allergy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/information#CD010638-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Olga Romantsik</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/information#CD010638-cr-0003">Maria Angela Tosca</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/information#CD010638-cr-0004">Simona Zappettini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010638.pub3/information#CD010638-cr-0005">Maria Grazia Calevo</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/information/en#CD010638-sec-0103">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 April 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010638.pub3">https://doi.org/10.1002/14651858.CD010638.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010638-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010638-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010638-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010638-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010638-abs-0003">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010638-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010638-abs-0001" lang="en"> <section id="CD010638-sec-0001"> <h3 class="title" id="CD010638-sec-0001">Background</h3> <p>Clinical egg allergy is a common food allergy. Current management relies upon strict allergen avoidance. Oral immunotherapy might be an optional treatment, through desensitization to egg allergen. </p> </section> <section id="CD010638-sec-0002"> <h3 class="title" id="CD010638-sec-0002">Objectives</h3> <p>To determine the efficacy and safety of oral and sublingual immunotherapy in children and adults with immunoglobulin E (IgE)‐mediated egg allergy as compared to a placebo treatment or an avoidance strategy. </p> </section> <section id="CD010638-sec-0003"> <h3 class="title" id="CD010638-sec-0003">Search methods</h3> <p>We searched 13 databases for journal articles, conference proceedings, theses and trials registers using a combination of subject headings and text words (last search 31 March 2017). </p> </section> <section id="CD010638-sec-0004"> <h3 class="title" id="CD010638-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) comparing oral immunotherapy or sublingual immunotherapy administered by any protocol with placebo or an elimination diet. Participants were children or adults with clinical egg allergy. </p> </section> <section id="CD010638-sec-0005"> <h3 class="title" id="CD010638-sec-0005">Data collection and analysis</h3> <p>We retrieved 97 studies from the electronic searches. We selected studies, extracted data and assessed the methodological quality. We attempted to contact the study investigators to obtain the unpublished data, wherever possible. We used the I² statistic to assess statistical heterogeneity. We estimated a pooled risk ratio (RR) with 95% confidence interval (CI) for each outcome using a Mantel‐Haenzel fixed‐effect model if statistical heterogeneity was low (I² value less than 50%). We rated the quality of evidence for all outcomes using GRADE. </p> </section> <section id="CD010638-sec-0006"> <h3 class="title" id="CD010638-sec-0006">Main results</h3> <p>We included 10 RCTs that met our inclusion criteria, that involved a total of 439 children (oral immunotherapy 249; control intervention 190), aged 1 year to 18 years. Each study used a different oral immunotherapy protocol; none used sublingual immunotherapy. Three studies used placebo and seven used an egg avoidance diet as the control. Primary outcomes were: an increased amount of egg that can be ingested and tolerated without adverse events while receiving allergen‐specific oral immunotherapy or sublingual immunotherapy, compared to control; and a complete recovery from egg allergy after completion of oral immunotherapy or sublingual immunotherapy, compared to control. Most children (82%) in the oral immunotherapy group could ingest a partial serving of egg (1 g to 7.5 g) compared to 10% of control group children (RR 7.48, 95% CI 4.91 to 11.38; RD 0.73, 95% CI 0.67 to 0.80). Fewer than half (45%) of children receiving oral immunotherapy were able to tolerate a full serving of egg compared to 10% of the control group (RR 4.25, 95% CI 2.77 to 6.53; RD 0.35, 95% CI 0.28 to 0.43). All 10 trials reported numbers of children with serious adverse events (SAEs) and numbers of children with mild‐to‐severe adverse events. SAEs requiring epinephrine/adrenaline presented in 21/249 (8.4%) of children in the oral immunotherapy group, and none in the control group. Mild‐to‐severe adverse events were frequent; 75% of children presented mild‐to‐severe adverse events during oral immunotherapy treatment versus 6.8% of the control group (RR 8.35, 95% CI 5.31 to 13.12). Of note, seven studies used an egg avoidance diet as the control. Adverse events occurred in 4.2% of children, which may relate to accidental ingestion of egg‐containing food. Three studies used a placebo control with adverse events present in 2.6% of children. Overall, there was inconsistent methodological rigour in the trials. All studies enrolled small numbers of children and used different methods to provide oral immunotherapy. Eight included studies were judged to be at high risk of bias in at least one domain. Furthermore, the quality of evidence was judged to be low due to small numbers of participants and events, and possible biases. </p> </section> <section id="CD010638-sec-0007"> <h3 class="title" id="CD010638-sec-0007">Authors' conclusions</h3> <p>Frequent and increasing exposure to egg over one to two years in people who are allergic to egg builds tolerance, with almost everyone becoming more tolerant compared with a minority in the control group and almost half of people being totally tolerant of egg by the end of treatment compared with 1 in 10 people who avoid egg. However, nearly all who received treatment experienced adverse events, mainly allergy‐related. We found that 1 in 12 children had serious allergic reactions requiring adrenaline, and some people gave up oral immunotherapy. It appears that oral immunotherapy for egg allergy is effective, but confidence in the trade‐off between benefits and harms is low; because there was a small number of trials with few participants, and methodological problems with some trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010638-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010638-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010638-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010638-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010638-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010638-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010638-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010638-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010638-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010638-abs-0005" lang="en"> <h3>Does giving daily small, steadily increasing amounts of egg protein help people with egg allergy? </h3> <p><b>Background</b> </p> <p>Until recently, the only practical option for people with food allergies was strict avoidance of foods to which they are allergic. It is difficult to avoid egg because it is found in many foods. Even with avoidance, the fear of accidentally eating foods with egg because of mislabelling or cross‐contamination is an ever‐present fear for even the most careful of people with food allergy. Accidentally eating egg‐containing foods can cause life‐threatening events. </p> <p>Oral immunotherapy is a new type of treatment for egg allergy, which is also known as oral desensitization or vaccination. Treatment involves consuming a small amount of egg protein daily, which is gradually increased over time until a full serving is reached. This method could alter the allergic response to the egg protein by the body’s immune system, increasing the amount of egg that can be eaten without inducing adverse reactions. </p> <p><b>Search date</b> </p> <p>We searched up to March 2017 for this update.</p> <p><b>Study characteristics</b> </p> <p>We included 10 randomized controlled trials (studies that allocate people randomly by chance to receive treatment) that compared oral immunotherapy to placebo (a fake treatment not containing egg) or an egg‐avoidance diet for people with egg allergy. The 10 studies included a total of 439 children (249 in the oral immunotherapy group (treatment containing egg) and 190 in the control group (no egg)) who were aged from 1 year to 18 years. </p> <p><b>Key results</b> </p> <p>The evidence showed that treating egg allergy by giving a small, increasing amount of egg may help most children with egg allergy to tolerate a partial serving of egg, so long as they continued to consume a daily amount of egg protein. Side effects were frequent during oral immunotherapy treatment, but were usually mild‐to‐moderate. Nevertheless, 21 of 249 children treated with oral immunotherapy for egg allergy required medicine because of a serious reaction. The studies did not report information about quality of life of children and their families during oral immunotherapy treatment. </p> <p><b>Quality of the evidence</b> </p> <p>The trials involved small numbers and there were problems with the way they were done, therefore further research is needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010638-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010638-sec-0093"></div> <h3 class="title" id="CD010638-sec-0094">Implications for practice</h3> <section id="CD010638-sec-0094"> <p>Studies to date involved few participants and evidence quality is low. Despite that, most children in the 10 included studies reached partial tolerance of egg. Moreover, some children were able to achieve full tolerance, and therefore, improved quality of life and nutritional requirements. </p> <p>Oral immunotherapy is very labour intensive and induces adverse allergic reactions in virtually all participants who are treated (although with mostly mild symptoms). Eosinophilic oesophagitis occurred in 10% to 15% of people treated with immunotherapy. A major difficulty of oral immunotherapy is the frequency of adverse events although most seem to be mild‐to‐moderate and self‐limiting. The use of parenteral epinephrine/adrenaline, as suggested by the guidelines in the case of a life‐threatening adverse event (<a href="./references#CD010638-bbs2-0043" title="MuraroA , WerfelT , Hoffman‐SommergruberK , RobertsG , BeyerK , Bindslev‐JensenC , et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy Asthma Proceedings2014;69(8):1008‐25. ">Muraro 2014</a>), is variable and may depend on oral immunotherapy protocol. Thus, physicians and their patients need to acknowledge and accept the risks of oral immunotherapy. Because there are no standardized protocols, guidelines based on high quality clinical trials would be required before incorporating desensitization into clinical practice. </p> </section> <h3 class="title" id="CD010638-sec-0095">Implications for research</h3> <section id="CD010638-sec-0095"> <p>Evidence quality was limited by small sample sizes and lack of methodological rigour. A larger randomized controlled trial that aims to eliminate selection, performance, and detection bias, would provide a more precise estimate of the treatment effect. Investigators should be encouraged to use a standard double‐blinded placebo‐controlled food challenge (DBPCFC) protocol, such as described by <a href="./references#CD010638-bbs2-0052" title="SampsonHA , Gerth van WijkR , Bindslev‐JensenC , SichererS , TeuberSS , BurksAW , et al. Standardizing double‐blind, placebo‐controlled oral food challenges: American Academy of Allergy, Asthma &amp; Immunology‐European Academy of Allergy and Clinical Immunology PRACTALL consensus report. Journal of Allergy and Clinical Immunology2012;130(6):1260‐74. ">Sampson 2012</a>, to enable better comparison of clinical trial outcomes and facilitate transition into practice. </p> <p>To date, there are few data available on oral immunotherapy in toddlers and no data on oral immunotherapy in adults. Given that some proportion of young egg‐allergic children tolerate heat‐denatured (baked) egg products, and the addition of these products to their diet appears to accelerate the development of tolerance with minimal adverse events, it may be safer and easier to identify these children and simply add baked‐egg products to their diets (more studies are needed in this area). </p> <p>All 10 included studies investigated oral immunotherapy. There is a gap in knowledge regarding sublingual immunotherapy which should be explored in future studies. </p> <p>In this review, adverse effects were difficult to quantify because of variability in reporting. Future studies should attempt to standardize reporting of adverse effects and to develop a consensus severity scale of adverse events could facilitate reporting. </p> <p>Safety of oral immunotherapy should be further rigorously and transparently investigated before oral immunotherapy could be applied in clinical practice. Futhermore, studies with longer follow‐up are needed to provide data relating to long‐term safety of oral immunotherapy. </p> <p>Further investigation of the mechanisms that lead to sustained unresponsiveness is also needed. Co‐interventions to decrease the rate of adverse effects may be key and need to be explored. The quality of life of people with allergies and their caregivers should be investigated and reported in a standardized manner. A cost‐effectiveness analysis is also needed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010638-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010638-sec-0029"></div> <div class="table" id="CD010638-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral and sublingual immunotherapy versus no therapy for egg allergy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral and sublingual immunotherapy versus no therapy for egg allergy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> children with egg allergy </p> <p><b>Setting:</b> hospitals <br/> <b>Intervention:</b> oral and sublingual immunotherapy for egg allergy. (Each study used a different oral immunotherapy protocol) </p> <p><b>Comparison:</b> placebo or egg‐free diet. (Three studies used placebo and seven studies used an egg avoidance diet as controls) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral immunotherapy versus no therapy for egg allergy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Increase in the amount of egg that could be tolerated</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 7.48</b> <br/> (4.91 to 11.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>410<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>82% of children in the oral immunotherapy group could ingest a partial serving of egg (1 g to 7.5 g) compared to 10% of the control group. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>763 per 1000</b><br/> (501 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complete recovery</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 4.25</b> <br/> (2.77 to 6.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>439<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>45% of children receiving oral immunotherapy were able to tolerate a full serving of egg compared to 10% of the control group. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>425 per 1000</b><br/> (277 to 653) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Numbers of children with serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All 10 trials reported numbers of children with serious adverse events (SAEs): SAEs requiring epinephrine/adrenaline occurred in 21/249 (8.4%) of children in the oral immunotherapy group and none in the control group. </p> <p>Because adverse events were classified differently among the studies, it is difficult to comment on whether they were under‐ or over‐estimated. Surprisingly, only one study showed a high level of SAEs (<a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>): 13 children required epinephrine/adrenaline administration 18 times, and one grade 5 reaction occurred. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of children with mild‐to‐severe adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 8.35</b> <br/> (5.31 to 13.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>439<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mild‐to‐severe adverse events were frequent; 75% of children presented mild‐to‐severe adverse events during oral immunotherapy treatment versus 6.8% of children in the control group. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>568 per 1000</b><br/> (361 to 892) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the risk of the control arm</p> <p><sup>1</sup> Downgraded one level because of risk of bias: all studies were assessed at high or unclear risk of bias in at least one domain.<br/> <sup>2</sup> Downgraded one level because of imprecision: few events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010638-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010638-sec-0030"></div> <p>This is an update of the 2014 version of this review. Please see the 'Differences between protocol and review' section for changes in the review since the protocol or the last version of the review. </p> <section id="CD010638-sec-0031"> <h3 class="title" id="CD010638-sec-0031">Description of the condition</h3> <p>Clinical egg allergy is one of the most common food allergies in western countries, affecting up to approximately 2% of young children (<a href="./references#CD010638-bbs2-0053" title="SavageJH , MatsuiEC , SkripakJM , WoodRA . The natural history of egg allergy. Journal of  Allergy and Clinical Immunology2007;120(6):1413‐7. ">Savage 2007</a>). <a href="./references#CD010638-bbs2-0047" title="OsborneNJ , KoplinJJ , MartinPE , GurrinLC , LoweAJ , MathesonMC , et al. HealthNuts Investigators. Prevalence of challenge‐proven IgE‐mediated food allergy using population‐based sampling and predetermined challenge criteria in infants. Journal of  Allergy and Clinical Immunology2011;127(3):668‐76. ">Osborne 2011</a> showed an 8.9% prevalence of challenge‐proven egg allergy in 12‐month old infants in Australia. Natural tolerance, that is, developing tolerance to egg over time, is common but some children will remain allergic until adulthood. Egg‐allergic reactions may persist throughout adulthood although symptoms may be milder. It has been shown that 75% to 85% of young children with egg allergy could tolerate heat‐denatured (baked) egg products, showing mild or no symptoms (<a href="./references#CD010638-bbs2-0042" title="LeonardSA , SampsonHA , SichererSH , NooneS , MoshierEL , GodboldJ , et al. Dietary baked egg accelerates resolution of egg allergy in children. Journal of Allergy and Clinical Immunology2012;130(2):473–80. ">Leonard 2012</a>; <a href="./references#CD010638-bbs2-0047" title="OsborneNJ , KoplinJJ , MartinPE , GurrinLC , LoweAJ , MathesonMC , et al. HealthNuts Investigators. Prevalence of challenge‐proven IgE‐mediated food allergy using population‐based sampling and predetermined challenge criteria in infants. Journal of  Allergy and Clinical Immunology2011;127(3):668‐76. ">Osborne 2011</a>); most outgrow the allergy. </p> <p>Despite this trend, recent data have shown that milk and egg allergies are becoming more persistent and that children may not be outgrowing these allergies until adolescence rather than during the first five to six years of life as previously thought (<a href="./references#CD010638-bbs2-0053" title="SavageJH , MatsuiEC , SkripakJM , WoodRA . The natural history of egg allergy. Journal of  Allergy and Clinical Immunology2007;120(6):1413‐7. ">Savage 2007</a>). It appears that the longer the egg allergy persists the less likely it is that tolerance will develop (<a href="./references#CD010638-bbs2-0058" title="WoodRA . The natural history of food allergy. Pediatrics2003;111(6 Pt 3):1631‐7. ">Wood 2003b</a>). Thus, it has become imperative to understand individualized prognoses of egg allergy and to develop clinical management that may improve the quality of life of egg‐allergic children and, ideally, promote earlier development of tolerance. It is likely that most children who tolerate baked‐egg products will develop tolerance after undergoing oral immunotherapy, and perhaps, this is achieved more rapidly if treated with oral immunotherapy (<a href="./references#CD010638-bbs2-0042" title="LeonardSA , SampsonHA , SichererSH , NooneS , MoshierEL , GodboldJ , et al. Dietary baked egg accelerates resolution of egg allergy in children. Journal of Allergy and Clinical Immunology2012;130(2):473–80. ">Leonard 2012</a>). Those children who do not tolerate heat‐denatured egg are likely to be more difficult to treat (<a href="./references#CD010638-bbs2-0042" title="LeonardSA , SampsonHA , SichererSH , NooneS , MoshierEL , GodboldJ , et al. Dietary baked egg accelerates resolution of egg allergy in children. Journal of Allergy and Clinical Immunology2012;130(2):473–80. ">Leonard 2012</a>). Consequently, an adequate placebo group is needed to investigate the ability of oral immunotherapy to induce long‐term tolerance. </p> <p>An immunoglobulin E (IgE)‐antibody mediated allergic reaction to egg is based on circulating levels of soluble IgE, which is produced by B cells and binds to the surface of mast cells and basophils. Mast cells are found in the skin, gut, and respiratory tract and are situated adjacent to nerves and blood vessels. Among the most important of their immune functions is the propensity to bind IgE, utilizing the high‐affinity IgE receptor FcåR1. When egg allergen is re‐encountered and recognized by cell‐bound IgE, adjacent FcåR1‐IgE complexes move closer together and bring their signalling machinery into close proximity, which sets off a cascade of phosphorylation ultimately resulting in calcium influx. When calcium enters the cell, the activated mast cell undergoes degranulation and the contents of these granules are released into the extracellular space. The immediate liberation of preformed powerful vaso‐active compounds such as histamine, platelet activating factor, tryptase, carboxypeptidase, chymase, and heparin, elicit the acute symptoms of type 1 hypersensitivity reactions in the skin, gut, respiratory, and cardiovascular systems (<a href="./references#CD010638-bbs2-0034" title="GalliSJ , TsaiM . Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. European Journal of Immunology2010;40(7):1843‐51. ">Galli 2010</a>). These symptoms include urticaria, angioedema, flushing, nausea, vomiting, abdominal pain, diarrhoea, wheezing, coughing and bronchospasm, rhinorrhoea, and hypotension or syncope, which can occur alone or in combination and typically begin within minutes and up to two hours after food ingestion (<a href="./references#CD010638-bbs2-0029" title="BurksAW . Peanut allergy. Lancet2008;371(9623):1538‐46. ">Burks 2008</a>; <a href="./references#CD010638-bbs2-0057" title="SimonsFE . Anaphylaxis pathogenesis and treatment. Allergy2011;66(Suppl 95):31‐4. ">Simons 2011</a>). </p> <p>There is no interventional therapy for egg allergy currently approved by the USA Food and Drug Administration (FDA), nor by the European Medicines Agency (EMA). Current management relies upon strict allergen avoidance, including the small quantities present in a variety of foods, and obvious sources such as desserts (<a href="./references#CD010638-bbs2-0043" title="MuraroA , WerfelT , Hoffman‐SommergruberK , RobertsG , BeyerK , Bindslev‐JensenC , et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy Asthma Proceedings2014;69(8):1008‐25. ">Muraro 2014</a>). In the USA, European Union, Australia, Japan, and Singapore, food‐labelling laws require food manufacturers to label packaging in plain language, listing the presence of common allergens and products (<a href="./references#CD010638-bbs2-0030" title="BurksAW , TangM , SichererS , MuraroA , EigenmannPA , EbisawaM , et al. ICON: food allergy. Journal of Allergy and Clinical Immunology2012;129(4):906‐20. ">Burks 2012a</a>). However, similar laws are not in place in many other countries, and in these settings, care is required to identify hidden forms of egg allergens, such as ovalbumin or ovomucoid (<a href="./references#CD010638-bbs2-0030" title="BurksAW , TangM , SichererS , MuraroA , EigenmannPA , EbisawaM , et al. ICON: food allergy. Journal of Allergy and Clinical Immunology2012;129(4):906‐20. ">Burks 2012a</a>). Studies that evaluated growth measurements against dietary records have suggested that food allergy puts children at risk of inadequate nutrition (<a href="./references#CD010638-bbs2-0031" title="ChristieL , HineRJ , ParkerJG , BurksW . Food allergies in children affect nutrient intake and growth. Journal of the American Dietetic Association2002;102(11):1648‐51. ">Christie 2002</a>). Specifically, where children's food allergy is concerned, it is advisable to involve a dietitian in formulating a nutritionally adequate, allergen‐free diet. The quality of life of people with food allergies and their caregivers is reduced due to the fear of incorrect labelling or accidentally ingesting egg‐containing food, and the ever‐present threat of anaphylaxis (<a href="./references#CD010638-bbs2-0032" title="CummingsAJ , KnibbRC , KingRM , LucasJS . The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. Allergy2010;65(8):933‐45. ">Cummings 2010</a>). The management of clinical egg allergy consists of teaching people with allergy and their carers to recognize the symptoms and signs of severe reaction, prompt use of epinephrine auto‐injection, and activation of emergency medicine assistance (<a href="./references#CD010638-bbs2-0056" title="SimonsFE . Anaphylaxis: Recent advances in assessment and treatment. Allergy and Clinical Immunology2009;124(4):625‐36. ">Simons 2009</a>). Therapeutic interventions that provide lifelong protection against potential egg ingestion are therefore required. </p> </section> <section id="CD010638-sec-0032"> <h3 class="title" id="CD010638-sec-0032">Description of the intervention</h3> <p>Traditional subcutaneous immunotherapy (also known as allergy shots) was studied since the early twentieth century and was able to induce desensitization (<a href="./references#CD010638-bbs2-0050" title="RinJ , GutermuthJ . 100 years of hyposensitization: history of allergen‐specific immunotherapy (ASIT). Allergy2011;66(6):713‐24. ">Ring 2011</a>). However, subcutaneous immunotherapy treatment is not feasible due to the high rate of systemic reactions (<a href="./references#CD010638-bbs2-0044" title="NelsonHS , LahrJ , RuleR , BockA , LeungD . Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. Journal of Allergy and Clinical Immunology1997;99(6 Pt 1):744‐51. ">Nelson 1997</a>; <a href="./references#CD010638-bbs2-0046" title="OppenheimerJJ , NelsonHS , BockSA , ChristensenF , LeungDY . Treatment of peanut allergy with rush immunotherapy. Journal of Allergy and Clinical Immunology1992;90(2):256‐62. ">Oppenheimer 1992</a>). Given the safety issues associated with subcutaneous immunotherapy, oral immunotherapy and sublingual immunotherapy have been studied as optional treatments. </p> <p>Although there have been reports in the literature over the last 100 years on the use of oral immunotherapy for food allergy, most research on this topic began with <a href="./references#CD010638-bbs2-0048" title="PatriarcaC , RomanoA , VenutiA , SchiavinoD , DiRienzoV , NuceraE , et al. Oral specific hyposensitization in the management of patients allergic to food. Allergologia et Immunopathologia1984;12(4):275‐81. ">Patriarca 1984</a>, who demonstrated the successful treatment of allergies to cow’s milk, egg, fish, and fruits with standardized oral immunotherapy protocols. In a pilot study of oral immunotherapy for egg allergy in children, Buchanan demonstrated the safety of a 24‐month egg oral immunotherapy protocol involving modified rush desensitization, build‐up, and maintenance phases (<a href="./references#CD010638-bbs2-0011" title="BuchananAD , GreenTD , JonesSM , ScurlockAM , ChristieL , AlthageKA , et al. Egg oral immunotherapy in non anaphylactic children with egg allergy. Journal of Allergy and Clinical Immunology2007;119(1):199‐205. ">Buchanan 2007</a>). </p> <p>The initial aim of oral immunotherapy is to provide clinical desensitization, that is, to achieve a state in which effector cells involved in a specific immune response develop reduced reactivity or become non‐reactive upon increased introduction of an allergen. In a desensitized state, a person may be non‐reactive while regularly receiving the allergen. However, when regular administration ends the previous level of reactivity returns. The aim of treatment is initially to desensitize people to egg allergen by increasing the threshold dose of exposure, and therefore, reduce the risk of anaphylaxis. The longer‐term goal is to induce a state of tolerance to an allergen where the non‐reactive state remains present permanently through down‐regulation of the TH2 response to egg, and which will endure irrespective of whether a previously clinically reactive person continues to consume egg products or not following the completion of the treatment (<a href="./references#CD010638-bbs2-0041" title="LandMH , KimEH , BurksAW . Oral desensitization for food hypersensitivity. Immunology and Allergy Clinics of North America2011;31(2):367‐76. ">Land 2011</a>). </p> <p>There are different types of oral immunotherapy protocols. Oral immunotherapy involves the regular administration of small amounts of allergen by the oral route to rapidly induce desensitization, then over time, induce tolerance to the allergen. </p> <p>Studies have considered immunotherapy that is ingested and immunotherapy administered sublingually. In this review, oral immunotherapy specifically refers to ingested immunotherapy and sublingual immunotherapy refers to immunotherapy administered under the tongue. </p> <p>People undergoing oral immunotherapy generally ingest a mixture of protein powder in a vehicle food (e.g. apple sauce). People undergoing sublingual immunotherapy generally receive a small amount of liquid extract under the tongue. Both treatments are typically initiated in a controlled setting where gradually increased doses of allergen are given up to a targeted dose. In standard protocols most dosing is subsequently done at home. </p> </section> <section id="CD010638-sec-0033"> <h3 class="title" id="CD010638-sec-0033">How the intervention might work</h3> <p>Oral immunotherapy involves the administration of initially very small doses (usually micrograms or milligrams) of food allergen to food‐allergic people in a controlled clinical setting. The dose of the administered food allergen is then systematically increased until a maximum tolerated dose is achieved (<a href="./references#CD010638-bbs2-0038" title="JonesSM , PonsL , RobertsJL , ScurlockAM , PerryTT , KulisM , et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. Journal of Allergy and Clinical Immunology2009;124(2):292‐300. ">Jones 2009</a>). Regular dosing with this maximal dose is then maintained at home by the person with the allergy (or their carer). Of note, it has been demonstrated that underlying the clinical benefits of oral immunotherapy were changes to multiple aspects of the immune system, leading to a dampened allergic response (<a href="./references#CD010638-bbs2-0038" title="JonesSM , PonsL , RobertsJL , ScurlockAM , PerryTT , KulisM , et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. Journal of Allergy and Clinical Immunology2009;124(2):292‐300. ">Jones 2009</a>). Changes included decrease in allergen‐specific IgE and increase in allergen‐specific IgG4 (<a href="./references#CD010638-bbs2-0011" title="BuchananAD , GreenTD , JonesSM , ScurlockAM , ChristieL , AlthageKA , et al. Egg oral immunotherapy in non anaphylactic children with egg allergy. Journal of Allergy and Clinical Immunology2007;119(1):199‐205. ">Buchanan 2007</a>; <a href="./references#CD010638-bbs2-0013" title="ItohN , ItagakiY , KuriharaK . Rush specific oral tolerance induction in school‐age children with severe egg allergy: One year follow up. Allergology International2010;59(1):43‐51. ">Itoh 2010</a>; <a href="./references#CD010638-bbs2-0049" title="PatriarcaG , NuceraE , RoncalloC , PollastriniE , BartolozziF , DePasqualeT , et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Alimentary Pharmacology and Therapeutics2003;17(3):459‐65. [Erratum in: Alimentary Pharmacology and Therapeutics. 2003 May 1;17(9):1205] ">Patriarca 2003</a>; <a href="./references#CD010638-bbs2-0020" title="StadenU , Rolinck‐WerninghausC , BreweF , WahnU , NiggemannB , BeyerK . Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy2007;62(11):1261‐9. ">Staden 2007</a>), as well as suppression of mast cells and basophils, an increase in T regulatory cells (TRegs), and a change in cytokine profile. Additionally, micro‐array analysis of T cells has revealed changes in several apoptotic pathways, although the significance of this result remains unknown (<a href="./references#CD010638-bbs2-0038" title="JonesSM , PonsL , RobertsJL , ScurlockAM , PerryTT , KulisM , et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. Journal of Allergy and Clinical Immunology2009;124(2):292‐300. ">Jones 2009</a>). Cytokine analysis demonstrated a clear decrease in TH2 cytokines without a concomitant increase in TH1 cytokines, causing a shift in TH1 and TH2 skewing and arguing against oral immunotherapy. Rather, a decrease in IL‐2 was noted, possibly suggesting clonal anergy or deletion as a possible mechanism of oral immunotherapy (<a href="./references#CD010638-bbs2-0041" title="LandMH , KimEH , BurksAW . Oral desensitization for food hypersensitivity. Immunology and Allergy Clinics of North America2011;31(2):367‐76. ">Land 2011</a>). However, caution needs to be applied when interpreting these results; both studies had small cohorts of participants and the selection criteria for the immunological studies were not sufficiently clear (<a href="./references#CD010638-bbs2-0038" title="JonesSM , PonsL , RobertsJL , ScurlockAM , PerryTT , KulisM , et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. Journal of Allergy and Clinical Immunology2009;124(2):292‐300. ">Jones 2009</a>; <a href="./references#CD010638-bbs2-0041" title="LandMH , KimEH , BurksAW . Oral desensitization for food hypersensitivity. Immunology and Allergy Clinics of North America2011;31(2):367‐76. ">Land 2011</a>). </p> <p>Successful desensitization is thought to induce immunological tolerance by generating allergen specific IL‐10 secreting Tr1 or TGF‐secreting TH3 regulatory T cells, or both (<a href="./references#CD010638-bbs2-0055" title="SichererSH , WoodRA , StableinD , BurksAW , LiuAH , JonesSM , et al. Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy. Journal of Allergy and Clinical Immunology2010;125(5):1077‐83. ">Sicherer 2010</a>). </p> </section> <section id="CD010638-sec-0034"> <h3 class="title" id="CD010638-sec-0034">Why it is important to do this review</h3> <p>Food allergy is an IgE‐mediated immediate‐type hypersensitivity that is thought to be the result of a breakdown in the normal process of oral tolerance. Although the prevalence of food allergy continues to rise, avoidance remains the standard of care because no disease‐modifying treatments are readily available. Although questions regarding the safety of treatments, and the potential for development of long‐term immunological tolerance remain, oral immunotherapy and sublingual immunotherapy offer potential hope for the future treatment of egg allergy. </p> <p>There is a need to systematically identify, critically appraise, and summarize the available evidence on the benefits and risks associated with oral immunotherapy and sublingual immunotherapy for the management of people with egg allergy. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010638-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010638-sec-0035"></div> <p>To determine the efficacy and safety of oral and sublingual immunotherapy in children and adults with immunoglobulin E (IgE)‐mediated egg allergy as compared to a placebo treatment or an avoidance strategy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010638-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010638-sec-0036"></div> <section id="CD010638-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010638-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs), quasi‐RCTs, and controlled clinical trials (CCTs) were eligible for inclusion. </p> </section> <section id="CD010638-sec-0039"> <h4 class="title">Types of participants</h4> <p>Children and adults diagnosed with an immediate‐type egg allergy were included. Egg allergy was defined as a history of systemic clinical reaction within minutes to hours after the ingestion of egg in people with objective evidence of sensitization to egg. Objective evidence was: </p> <p> <ol id="CD010638-list-0001"> <li> <p>a positive skin prick test (SPT) or the presence of specific IgE; and</p> </li> <li> <p>a positive open or double‐blind, placebo‐controlled food challenge. The positive reaction to the challenge should be the immediate onset of symptoms suggestive of IgE‐mediated mechanisms such as urticaria, angioedema, vomiting, diarrhoea, abdominal pain, and any alteration in the level of consciousness. </p> </li> </ol> </p> </section> <section id="CD010638-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Egg oral immunotherapy or sublingual immunotherapy administered by any protocol compared with a placebo group, or treatment with a continued avoidance diet. </p> </section> <section id="CD010638-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD010638-sec-0042"> <h5 class="title">Primary outcomes</h5> <p>Successful desensitization or achieved tolerance defined as:</p> <p> <ol id="CD010638-list-0002"> <li> <p>an increase in the amount of egg that can be ingested and tolerated without adverse reaction (i.e. evidence of desensitization); </p> </li> <li> <p>a complete recovery from egg allergy whether or not egg is eaten (i.e. induction of immunologic tolerance); </p> </li> <li> <p>numbers of participants with serious adverse events; and</p> </li> <li> <p>numbers of participants with mild‐to‐severe adverse events.</p> </li> </ol> </p> </section> <section id="CD010638-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010638-list-0003"> <li> <p>Medication used due to adverse events.</p> </li> <li> <p>Immunological changes suggestive of the induction of tolerance (e.g. decreased wheal diameter on SPT testing with egg, decreased egg‐specific IgE levels, increased egg‐specific IgG4 levels. </p> </li> <li> <p>Change in quality of life.</p> </li> <li> <p>Cost‐effectiveness of treatment.</p> </li> </ol> </p> </section> </section> </section> <section id="CD010638-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>We conducted systematic searches for RCTs, quasi‐RCTs, and CCTs regardless of language, geographical area, or publication status to 31 March 2017. </p> <section id="CD010638-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched: the Cochrane Library, MEDLINE, Embase, PubMed, ISI Web of Science, Google Scholar, AMED, BIOSIS, CAB, CINAHL, Global Health, TRIP, and WHO Global Health Library. The MEDLINE search strategies are detailed in <a href="./appendices#CD010638-sec-0099">Appendix 1</a> and the search strategies used for other databases are presented in <a href="./appendices#CD010638-sec-0100">Appendix 2</a>. We combined subject search strategies with adaptations of the highly sensitive search strategy designed by Cochrane for identifying RCTs and CCTs as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.1.0, Box 6.4.b (<a href="./references#CD010638-bbs2-0036" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010638-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We identified unpublished studies, ongoing work and research in progress by searching key trials registers ( ISRCTN registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>).; <a href="http://www.clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). We also searched the proceedings of conferences important to allergy and immunology and not included in the electronic databases. We used key articles retrieved from the electronic database searches (including seminal research studies and review articles) to conduct citation searches in Web of Science and Scopus. We searched for grey literature via Google Scholar (<a href="http://scholar.google.com" target="_blank">scholar.google.com</a>) and contacted experts in the field. </p> </section> </section> <section id="CD010638-sec-0047"> <h3 class="title" id="CD010638-sec-0047">Data collection and analysis</h3> <section id="CD010638-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (OR, MAT) independently screened the retrieved titles and abstracts of records and excluded irrelevant ones. We retrieved the full text of reports of potentially relevant studies. Multiple reports from the same study were identified and grouped under a single study identifier. Two review authors (OR, MGC) independently undertook the examination of studies and selection based on the eligibility criteria. If required, study investigators were contacted to clarify eligibility. If the two review authors did not agree on including a study, even after discussion, a third author acted as an arbiter (SZ). </p> </section> <section id="CD010638-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>We created a data extraction form that included the following items: trial characteristics (setting, oral immunotherapy regimen, eligibility criteria); methodological quality (randomization, blinding, selective reporting); participant characteristics; results and outcomes. The form was piloted using two sample studies. Two review authors (OR, MGC) working independently, extracted data. We contacted study investigators when information was not available from study reports. Disagreements between review authors were resolved by discussion and, if required, arbitration by a third review author (SZ). </p> </section> <section id="CD010638-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SZ, MGC) worked independently using Cochrane’s risk of bias tool to evaluate each included study. We considered the following types of potential bias: selection bias (adequacy of randomization and allocation concealment); performance bias (blinding of participants and personnel); detection bias (blinding of outcome assessors); and attrition bias (loss to follow‐up). Any disagreements were discussed and a third review author acted as arbiter if necessary. Assessment results were summarized in 'Risk of bias' tables. We performed sensitivity analyses to determine the influence of studies with high risk of bias on meta‐analysis results. </p> </section> <section id="CD010638-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>Categorical data were extracted for each intervention group, and risk ratios (RRs) and absolute risk differences (RDs) calculated. Mean and standard deviation were obtained for continuous data and analyses performed using the mean differences (MDs). For each measure of effect the 95% confidence intervals (CI) were given. The number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH) were presented when RDs were statistically significant. </p> </section> <section id="CD010638-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>We did not anticipate any unit of analysis issues for this intervention. For example, cross‐over trials would not be a rational approach to assess immunotherapy because the goal of treatment is to induce tolerance, and a participant would not be able to serve as their own control if their immune response had been altered. We did not expect large numbers of egg‐allergic people from various cohorts, so cluster‐randomization was unlikely to be encountered. </p> </section> <section id="CD010638-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact study investigators to request missing data. Data were analysed on an intention‐to‐treat (ITT) basis whenever possible. </p> </section> <section id="CD010638-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We anticipated clinical heterogeneity in the studies that were reviewed, including the ages of the study population and differences in the immunotherapy protocol. However, despite these potential differences we believe that we were able to analyse the studies together to assess the efficacy of oral immunotherapy. We assessed statistical heterogeneity using the I² statistic (<a href="./references#CD010638-bbs2-0036" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>); an I² value greater than 50% implies substantial heterogeneity. </p> </section> <section id="CD010638-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess reporting and publication bias by examining the degree of asymmetry of a funnel plot in RevMan 5.3 provided that a sufficient number of studies (n &gt; 10) were available (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010061.pub2/full#CD010061-bbs2-0039" target="_blank">RevMan 2014</a>). However, this was not feasible. </p> </section> <section id="CD010638-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We used a Mantel‐Haenszel fixed‐effect model for meta‐analysis, and summarized evidence in a 'Summary of findings' table. All analyses were conducted using Review Manager (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010061.pub2/full#CD010061-bbs2-0039" target="_blank">RevMan 2014</a>). </p> </section> <section id="CD010638-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Depending on the data available, we planned to undertake subgroup analyses for: presence of asthma, other food allergies, history of previous anaphylaxis, the oral immunotherapy or sublingual immunotherapy regimen, duration of treatment, time since completion of treatment, and RCT versus non‐RCT. However, there were insufficient data for subgroup analysis to be performed. </p> </section> <section id="CD010638-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>A sensitivity analysis was performed for reviewed studies that were deemed at high risk of bias mainly in two domains: detection and performance biases. </p> <section id="CD010638-sec-0059"> <h5 class="title">'Summary of findings' table</h5> <p>Following standard Cochrane methodology, we created a 'Summary of findings' table for all of our outcomes. Also following standard Cochrane methodology, we assessed the quality of evidence for each outcome using the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias (<a href="./references#CD010638-bbs2-0035" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a>)). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010638-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010638-sec-0060"></div> <section id="CD010638-sec-0061"> <h3 class="title">Description of studies</h3> <section id="CD010638-sec-0062"> <h4 class="title">Results of the search</h4> <p>The electronic searches from the previous version of the review and this update retrieved 96 records, of which 85 remained after removing duplicates. Two review authors screened the records based on title and abstract and excluded 59 records. We obtained the full‐text articles for 26 records. Of these, we excluded 11 trials that did not meet our inclusion criteria. Five studies are awaiting classification, and two were ongoing studies. We included 10 studies from 11 records in this review update (<a href="#CD010638-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010638-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010638-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010638-sec-0063"> <h4 class="title">Included studies</h4> <p>We included 10 published studies that met our inclusion criteria; of these, six studies (including 272 children) were added for this update (see <a href="./references#CD010638-sec-0109" title="">Characteristics of included studies</a>). The studies recruited a total of 439 children (249 intervention/190 control) who were aged from 1 to 18 years. </p> <p>Three studies used placebo control (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>), and seven studies used an avoidance diet as the control (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). </p> <p>Five studies excluded children with history of anaphylaxis (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015;</a><a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>), but two studies included children with history of anaphylaxis (<a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>). Anaphylaxis history was not clearly defined in the inclusion criteria of three studies (<a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015;</a><a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013;</a><a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). </p> <p>Four studies excluded children with severe or uncontrolled asthma (<a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). One study excluded children with severe atopic dermatitis (<a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). Two studies excluded children with egg non IgE mediated adverse events, eosinophilic oesophagitis, immune system diseases or malignant diseases, any baseline disease contra‐indicating the use of epinephrine and/or allergy to any component of the placebo (<a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015;</a><a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). Children were excluded based on: diagnosis of cardiovascular disease (<a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>), neuropsychiatric impairment (<a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>), receiving any other immunotherapy (<a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>), significant pre‐ and post‐natal diseases (although significance was not defined) (<a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>), use of systemic drugs (such as antihistamines, beta‐agonists, ACE‐inhibitors) (<a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>), congenital illness or malformation that may affect normal growth (<a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>), and participation in another clinical trial (<a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>). Two studies excluded children with parental history of unreliable management of complications and treatment (<a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>). </p> <p>Two studies administered antihistamine treatment as a co‐intervention (<a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). Oral immunotherapy was used in combination with antihistamines if recurrent allergic symptoms developed in <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>. Children with asthma on preventive treatment continued therapy during oral immunotherapy in <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>. Two studies did not report exclusion criteria (<a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>). </p> <section id="CD010638-sec-0064"> <h5 class="title">Oral immunotherapy protocols</h5> <p>Egg oral immunotherapy protocols differed. Nine studies included a build‐up phase in a hospital, day treatment centre, or research centre followed by gradual up‐dosing in hospital or at home, and a maintenance phase at home (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a> reported that the oral immunotherapy protocol was carried out at home only. <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> was characterized by an increasing dose in research settings followed by an approximate doubling every 30 minutes, up to 50 mg. The maximum tolerated single dose of egg was given in the clinic on the following day and provided the starting dose for the build‐up phase. Attainment of a minimum dose of 3 mg of egg white powder was required to continue dosing. The children then continued a build‐up dosing at home. For children who did not achieve a dose of 50 mg on the first day, doses were doubled every two weeks up to 50 mg. Therefore, the dose was increased to 75 mg with following increases by 25% up to 2 g. The maximum time allowed for the build‐up phase was 10 months; the dose achieved at 10 months was considered to be the maintenance dose. After reaching their highest build‐up dose (maximum 2 g), children continued this dose daily for at least two months before the month 10 oral food challenge; children in the egg oral immunotherapy group continued maintenance dosing through to 22 months. The <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a> protocol included in‐hospital administration of 1 mg egg and was continued by tripling the dose every 30 minutes, up to 30 mg. On the second day, 30 mg was administered in one single dose, with treatment continuing at home at the same dose. Subsequently, weekly increases were made in the clinic until 10 g of powdered egg, the equivalent of one egg, was reached. In <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a> children started with one drop of undiluted raw hen's egg emulsion (0.015 mL) in a day hospital then continued at home with gradually increasing doses. The doses were increased at six further day hospital visits (on days 8, 29, 64, 92, 134, 176). Dose increases were customized based on the frequency and severity of side effects and in cases of intercurrent illness or worsening asthma. The oral immunotherapy protocol in <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> started with 0.27 mg of hen's egg protein in hospital and thereafter children doubled the dose at home every eight days until day 80. Subsequently, the doses were doubled every 16 days to achieve a total daily intake of 25 mL at six months. In the <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> oral immunotherapy protocol, pasteurized liquid egg white containing 8.3 g of protein per 100 mL was used, in which allergenicity was equivalent to raw egg white. The induction phase involved 16 weeks and started with a 2‐day in‐hospital rush phase, in which doses were increased hourly, starting with 0.083 mg egg white protein. Children were then discharged home and continued receiving the last tolerated dose once daily throughout the week. Weekly increases were given at the outpatient clinic until the equivalent of one raw egg (60 g of fresh product) could be given. The <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> oral immunotherapy procedure consisted of weekly administration, at the hospital clinic, of increasing doses of dehydrated egg white, diluted with sterile saline, starting with 0.1 mg. The dose was doubled every week until week 16, to achieve a cumulative dose of 4 g in approximately four months. When the dose of 4 g was tolerated, the oral immunotherapy protocol was continued with cooked or boiled egg at home. The <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> protocol followed the procedure described in <a href="./references#CD010638-bbs2-0020" title="StadenU , Rolinck‐WerninghausC , BreweF , WahnU , NiggemannB , BeyerK . Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy2007;62(11):1261‐9. ">Staden 2007</a>, which consisted of an initial dose escalation phase in hospital starting with 0.08 mg of egg white and subsequently increasing every 20 minutes up to 140 mg of egg white protein (cumulative dose was 280 mg). This was followed by a build‐up phase with a weekly increase of the last maximum tolerated dose in hospital up to 2.8 g of egg white protein and a maintenance phase, which consisted in consumption of at least one undercooked egg (defined by the authors as fried egg, scrambled or undercooked omelet) every 48 hours. Children were permitted to freely consume any other egg‐containing food. The <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> oral immunotherapy protocol was characterized by an escalation phase in hospital increasing the dose of hydrolysed egg every 20 to 30 minutes to reach 9 ± 1 g of hydrolysed egg. In the absence of adverse events the child received the full dose of 9 ± 1 g of hydrolysed egg, and in the absence of adverse events occurring, the child received the full dose of hydrolysed egg daily for six months. The <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a> oral immunotherapy protocol involved a consecutive five day build‐up phase starting with a highest tolerated single dose at the baseline egg double‐blinded placebo‐controlled food challenge test (DBPCFC). This consisted in an escalation dose of egg white starting from 4 mg and finishing with 1.8 g of egg white every 20 minutes until objective IgE‐mediated manifestations or subjective mild‐to‐moderate symptoms occurred. The regimen was conducted in an outpatient clinic. The build‐up target was 3.6 g of dehydrated egg white with a cumulative dose of 5.4 g administered on the last day. The maintenance phase consisted in eating one undercooked egg every 48 hours. Moreover, children were permitted to freely consume any other egg‐containing food. In <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>, oral immunotherapy was carried out at home with a starting dose of 0.1 mg of dried powdered egg and this was increased up to 4 g with three to four days interval. The escalation protocol was based on the method used in <a href="./references#CD010638-bbs2-0049" title="PatriarcaG , NuceraE , RoncalloC , PollastriniE , BartolozziF , DePasqualeT , et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Alimentary Pharmacology and Therapeutics2003;17(3):459‐65. [Erratum in: Alimentary Pharmacology and Therapeutics. 2003 May 1;17(9):1205] ">Patriarca 2003</a>. Children were permitted to continue oral immunotherapy in combination with antihistamines in case of recurrent allergic symptoms. </p> <p>Each study used a different egg preparation: <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> used raw white egg powder. <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a> used powdered pasteurized egg. <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a> and <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> used raw egg emulsion. <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> used pasteurized liquid egg white. <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>, <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> and <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a> used dehydrated egg white. <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> used hydrolysed egg. <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a> used dried powdered egg. </p> <p>There were also differences among included studies regarding the duration of oral immunotherapy to achieve full desensitization, defined as the ability to digest a small egg serving without adverse events. <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> reported desensitization in 75% of children after 22 months of oral immunotherapy; the target maintenance dose was 10 g egg white powder. Desensitization was evaluated by oral food challenge test. The duration of oral immunotherapy in <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a> varied between four and 28 weeks (average 10 weeks) targeted to achieve a tolerance of 10 g of whole egg. The <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a> oral immunotherapy protocol duration, to achieve "maximum tolerance" by digesting 40 mL or raw egg emulsion without adverse events, was six months. Desensitization was evaluated by a DBPCFC test. The planned duration of oral immunotherapy for children to be able to tolerate 25 mL of raw egg in <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> was 181 days. The actual duration of the oral immunotherapy was longer, with a mean duration of 215 days (range 178 to 287 days). None of the oral food challenge tests were performed for the intervention group at the end of the study; only children in the control group underwent DBPCFC at six months after enrolment. The duration of oral immunotherapy in <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> was 12 months and desensitization was evaluated by oral food challenge to one raw egg, meaning 3.8 g of raw egg white or if not reached, the highest tolerated dose. The oral immunotherapy protocol in <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> aimed to achieve a tolerance a 4 g of dehydrated egg white in approximately four months and DBPCFC performed by the end of the study. Desensitized children received an egg‐containing diet with two to three eggs per week for six months, following a three‐month egg avoidance diet, after which a repeat DBPCFC was performed (<a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>). In <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>, the primary study outcome was to assess the induction of sustained unresponsiveness after three months of egg oral immunotherapy and an egg avoidance diet for one month, defined as the ability to consume 2808 mg of egg white protein without symptoms in a DBPCFC at four months. The oral immunotherapy duration in <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> was six months with the target to tolerate 43.2 g of boiled egg on oral food challenge. The <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a> study was randomized for the first five months, during which an intervention group of children received egg oral immunotherapy shortly after randomization and control group children were on an egg avoidance diet; thereafter the control group was stopped and control group children who failed DBPCFC at five months began an oral immunotherapy treatment. The results reported here were extracted from the first five months of the randomized study period. No food challenge test was performed on children in the oral immunotherapy group at five months. <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a> used an oral immunotherapy protocol that lasted on average 6.5 months (range 5 to 8) aiming to achieve tolerance of 4 g dry egg powder on oral food challenge by the end of the oral immunotherapy protocol. </p> <p>Clinical history of allergic reactions after egg digestion was an inclusion criterion for all studies. In two studies, positive clinical history was defined as development of symptoms within two hours after ingestion of egg (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012;</a><a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>), and in one study the definition was as an immediate (&lt; 1 h) reaction following egg ingestion (<a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>). </p> <p>Nine studies reported as one of the inclusion criteria a positive skin prick test (SPT) (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). Positive egg‐specific IgE (sIgE) levels was an inclusion criteria in all ten studies although the definition, if it was specified, varied among the studies. In <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> more than 5 kU/L for participants six years of age or older, or 12 kU/L or more for those five years old; in <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> and in <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> it was considered positive level of 0.35 kU/L or higher; <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>, <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>, <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a> defined IgE positivity if the levels were of 0.7 kU/L or higher. In seven studies DBPCFC was performed at baseline (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a><a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015;</a><a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013;</a><a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015;</a><a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013;</a><a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a><a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). Two studies required oral food challenge at baseline (<a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> and <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>); oral food challenge was not performed at baseline in <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>. </p> <p>In seven studies a DBPCFC test was performed on all children in the control group at the end of the study (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). In three of these seven studies, DBPCFC was also performed for oral immunotherapy group participants (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>). An open oral food challenge was performed in oral immunotherapy group participants at the end of the study in five trials (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>) and in two trials it was performed in control group participants (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>). </p> <p>The follow‐up period varied for each study, and included: 36 months (<a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>), 24 months (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>), 13 months (<a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>), 12 months (<a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>), six months (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>, <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>) and five months (<a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). All children were receiving daily maintenance at the time of follow‐up. </p> </section> <section id="CD010638-sec-0065"> <h5 class="title">Study funding sources</h5> <p>Two included RCTs did not receive financial support (<a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>). Two studies were supported by national research grants (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a> was supported by a Merck Sereno grant and by a grant from the ALK‐Abelló pharmaceutical company. <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> was not funded, but the English language publication was financially supported by Stallergenes pharmaceutical company. Some authors of the <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> study are or were employees for Nestec Ltd. <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a> declared that the study was partially supported by a grant from the Ministry of Health, Labour and Welfare Japan, and funds from a Research Center of Taiho Pharmaceutical Company. Study funding sources were not reported for two studies (<a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>). </p> </section> <section id="CD010638-sec-0066"> <h5 class="title">Withdrawal rate</h5> <p>We calculated the withdrawal rate for each study. The main reason for withdrawal was the occurrence of adverse events. Interestingly, <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> reported one dropout due to anxiety. In <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> the dropout rate was 15% for children in the oral immunotherapy group and 13% for placebo group children; the overall withdrawal rate for both study groups was 14.5%. <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a> reported a 4% overall dropout rate (7.5% for the oral immunotherapy group and 0% for the placebo group). <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> reported an overall 5% dropout rate, with 10% in the oral immunotherapy group and 0% in the control group. There were no dropouts in <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>. <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> reported 18% withdrawal in the oral immunotherapy group and none in the control group, resulting in an overall withdrawal of 11%. <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> reported an overall dropout rate of 13% (6% for the oral immunotherapy group and 21% for the placebo group). <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> had a 7% dropout rate in the oral immunotherapy group and none in the control group, the overall withdrawal rate being 3%. <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> reported a 27% withdrawal rate in the oral immunotherapy group and none in the control group; overall withdrawal: 14%. In <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>, the overall withdrawal rate was 9%: 10.5% in the oral immunotherapy group and 7% in the placebo group. <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a> had an overall withdrawal rate of 17%: 22% in the oral immunotherapy group and 11% in the placebo group. </p> </section> </section> <section id="CD010638-sec-0067"> <h4 class="title">Excluded studies</h4> <p>We excluded 11 studies that did not meet our inclusion criteria. The reasons for exclusion were: no previous history of exposure to egg (one study); comparison group not placebo or a continued avoidance diet (seven studies); results were for combined egg and milk‐allergic participants (three studies). See <a href="./references#CD010638-sec-0110" title="">Characteristics of excluded studies</a>. </p> <section id="CD010638-sec-0068"> <h5 class="title">Studies awaiting classification</h5> <p>Our rsearch revealed abstracts for five studies with insufficient information to assess eligibility. See <a href="./references#CD010638-sec-0111" title="">Characteristics of studies awaiting classification</a>. </p> </section> <section id="CD010638-sec-0069"> <h5 class="title">Ongoing studies</h5> <p>Searches of clinical trials registers identified two potentially relevant trials (<a href="./references#CD010638-bbs2-0028" title="Cow's milk and hen's egg hyposensitization in adults. Ongoing studyApril 2015. ">NCT02083471</a>; <a href="./references#CD010638-bbs2-0027" title="Oral desensitization to egg with subsequent induction of sustained unresponsiveness for egg‐allergic children using baked egg or egg oral immunotherapy. Ongoing studyJuly 2013. ">NCT01846208</a>; <a href="./references#CD010638-sec-0112" title="">Characteristics of ongoing studies</a>). These will be assessed for inclusion in a future review update following completion of the studies. </p> </section> </section> </section> <section id="CD010638-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <p>We analysed seven domains of potential risk of bias for the included studies. The risk of bias decisions are shown in <a href="./references#CD010638-sec-0109" title="">Characteristics of included studies</a>, and summarized in <a href="#CD010638-fig-0002">Figure 2</a> and <a href="#CD010638-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010638-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010638-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010638-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010638-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010638-sec-0071"> <h4 class="title">Allocation</h4> <p>Eight included studies (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>) provided a description of an adequately generated random sequence and were judged to be at low risk of bias. We judged one study (<a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>) to be at unclear risk of bias due to insufficient information. One study was assessed at high risk of bias because participants were divided into two groups (active or control group) based on parent's choice (<a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). </p> <p>Six included studies provided a description of an adequately concealed allocation and were judged to be at low risk of bias (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>). We judged three studies to be at an unclear risk of bias due to insufficient information (<a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). One study was assessed at high risk of bias because participants were divided into two groups (active or control group) based on parent's choice (<a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). </p> </section> <section id="CD010638-sec-0072"> <h4 class="title">Blinding</h4> <p>No studies were assessed at low risk of detection bias. Two studies were at low risk of bias for participant and personnel blinding (<a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>). Eight studies were assessed at high risk of bias for this domain (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>), but seven used egg avoidance as a control, making blinding impossible. No studies were assessed at low risk of bias for blinding outcome assessment (detection bias), but was at high risk in seven studies (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). Three studies were assessed at unclear risk of bias for this domain (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>). </p> </section> <section id="CD010638-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies were assessed at high risk of attrition bias because there was an imbalance in numbers for missing data across intervention groups (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>). Seven studies were assessed at low risk of attrition bias because of low levels of attrition or because attrition was equal between groups (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>) . </p> </section> <section id="CD010638-sec-0074"> <h4 class="title">Selective reporting</h4> <p>Protocols were available for three studies and were assessed at low risk of bias (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>). Seven studies did not provide clear pre‐specified outcomes and were assessed at unclear risk of bias (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). </p> </section> <section id="CD010638-sec-0075"> <h4 class="title">Other potential sources of bias</h4> <p>The included studies appeared free of other sources of bias.</p> </section> </section> <section id="CD010638-sec-0076"> <h3 class="title" id="CD010638-sec-0076">Effects of interventions</h3> <p>See: <a href="./full#CD010638-tbl-0001"><b>Summary of findings for the main comparison</b> Oral and sublingual immunotherapy versus no therapy for egg allergy</a> </p> <section id="CD010638-sec-0077"> <h4 class="title">Increase in the amount of egg that could be tolerated (Analysis 1.1)</h4> <p>We pooled nine studies (410 children: 234 intervention/176 control). Most children (82%) in the oral immunotherapy group could ingest a partial serving of egg (1 g to 7.5 g) compared to 10% of the control group (RR 7.48, 95% CI 4.91 to 11.38; RD 0.73, 95% CI 0.67 to 0.80; children = 410; studies = 9; I² = 27% for RR and I² = 73% for RD). Children who did not reach complete desensitization at the end of oral immunotherapy tolerated a higher quantity of egg powder compared to baseline: 4000 mg versus 600 mg (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>); 100.8 mg versus 481.3 mg (<a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>). Four children (8%) in <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> achieved partial desensitization, defined as the ability to digest 0.8 g to1.7 g of raw egg white protein. Partial tolerance (&lt; 40 mL but &gt; 10 mL raw egg emulsion) was achieved in 90% of children in the oral immunotherapy group in <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>. Although 80% of children in <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> achieved intake of 25 mL of raw egg, only 30% who reached the full target dose of 25 mL raw egg without any symptoms and 50% of children presented some symptoms with duration &lt; 2 h and spontaneous resolution. The tolerated egg quantity was not reported in four studies (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>, <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). Our GRADE assessment judged the quality of evidence to be low. </p> </section> <section id="CD010638-sec-0078"> <h4 class="title">Complete recovery (Analysis 1.2)</h4> <p>All 10 included trials (N = 439; 249 intervention/190 control) reported this outcome. <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> reported desensitization in 75% of children after 22 months of oral immunotherapy; the target maintenance dose was 10 g egg white powder. Of note, the data from long‐term follow‐up of the <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> RCT participants who continued to receive oral immunotherapy daily demonstrated that 45% (18/40 oral immunotherapy‐treated participants) achieved sustained unresponsiveness by year 3, and 50% (20/40 oral immunotherapy‐treated participants) by year 4 (<a href="./references#CD010638-bbs2-0039" title="JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Jones 2016</a>). <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a> reported that 92.5% of children achieved the desired tolerance of 10 g of whole egg. However, only 54% of children who completed the protocol had a good tolerance on the oral food challenge test with raw egg six months after finishing oral immunotherapy, and were allowed a diet containing egg without any restrictions. <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a> used a six month oral immunotherapy protocol duration to achieve "maximum tolerance" by digesting 40 mL or raw egg emulsion without adverse events. None of the children could tolerate 40 mL of raw egg emulsion by the end of the oral immunotherapy protocol. In <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> at the end of the oral immunotherapy protocol 80% of children were able to tolerate 25 mL of raw egg. Of note, just 30% of children (N = 3) tolerated a full raw egg dose without symptoms; 50% of children continued to have some symptoms shortly after digesting the target amount of raw egg. Complete desensitization in <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> (which was evaluated by oral food challenge to one raw egg, meaning 3.8 g raw egg white) was achieved in 54% of children (N = 28). The oral immunotherapy protocol in <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> aimed to achieve a tolerance a 4 g of dehydrated egg white and 95% of children were successfully desensitized. Desensitized children were placed on an egg‐containing diet with two to three eggs per week for six months, following a three‐month egg avoidance diet. DBPCFC after this time period showed that only 31% of children (5/16 children) maintained the achieved tolerance; the remaining 69% (11/16) lost their desensitization and reacted to egg (<a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>). </p> <p>In <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>, sustained unresponsiveness, defined as the ability to consume 2808 mg of egg white protein without symptoms in a DBPCFC by the end of the oral immunotherapy protocol was achieved in 37% of oral immunotherapy children. These children were allowed to regularly consume food containing egg and at least two undercooked eggs per week. <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> aimed to tolerate 43.2 g of boiled egg by the end of the oral immunotherapy protocol and 36% of the children had a negative egg oral food challenge test. </p> <p>The <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a> study reported complete desensitization, defined as ability to consume one undercooked egg (fried, scrambled, or omelet) without or with only mild adverse events every 48 hours, was achieved in 89.5% of oral immunotherapy group children by the end of the oral immunotherapy. <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a> used an oral immunotherapy protocol that was aiming to achieve tolerance of 4 g dry egg powder on oral food challenge: 57% of oral immunotherapy children reached complete desensitization. </p> <p>A total of 439 children were analyzed (249 intervention/190 control). Fewer than half (45%) of children receiving oral immunotherapy were able to tolerate a full serving of egg compared to 10% of the control group (RR 4.25, 95% CI 2.77 to 6.53; RD 0.35, 95% CI 0.28 to 0.43; children = 439; studies = 10; I² = 22% for RR and I² = 86% for RD). Spontaneous tolerance, defined as the spontaneous resolution of egg allergy without applying specific treatments, was achieved in a total of 19 children: in <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a> (7 children); <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> (5 children); <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> (3 children); <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> (2 children); <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> (1 child) and <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> (1 child). Our GRADE assessment judged the quality of evidence to be low. </p> </section> <section id="CD010638-sec-0079"> <h4 class="title">Adverse effects</h4> <section id="CD010638-sec-0080"> <h5 class="title">Number of participants with serious adverse events (SAEs) (Analysis 1.3)</h5> <p>All 10 included trials (N = 439) reported occurrence of serious adverse events. A total of 21 children required epinephrine/adrenaline treatment (<a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>, N = 13; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>, N = 5; 1 each in <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> and <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>). In total, 21 (8.4%) of the 249 children receiving oral immunotherapy required epinephrine. No children in the control group required epinephrine. Our GRADE assessment judged the quality of evidence to be low. </p> </section> <section id="CD010638-sec-0081"> <h5 class="title">Number of participants with mild‐to‐severe adverse events (Analysis 1.4)</h5> <p>All included trials (N = 439) reported occurrence of mild‐to‐severe adverse events (RR 8.35, 95% CI 5.31 to 13.12; RD 0.67, 95% CI 0.61 to 0.73; children = 439; studies = 10; I² = 29% for RR and I² = 82% for RD). Although all studies provided detailed reports of adverse events, there was significant heterogeneity in methods of reporting. Adverse events occurred most frequently either in the oral immunotherapy escalation phase or in association with oral immunotherapy dosing. Seventy‐five per cent of children presented with mild‐to‐severe adverse events during oral immunotherapy treatment versus 6.8% of control group children. Based on available data, we could not comment on whether over‐ or under‐reporting of adverse events is a concern, although this is a possibility. Our GRADE assessment judged the quality of evidence to be low. </p> <p>In <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> (N = 55) adverse events rates were highest during the first 10 months of oral immunotherapy. However, no serious adverse events or need for epinephrine were reported. Adverse events, most of which were oral or pharyngeal, were associated with 25% of 11,860 doses of oral immunotherapy with egg and 3.9% of 4018 doses of placebo. In the oral immunotherapy group 78% of children had oral or pharyngeal adverse events compared with 20% in the placebo group (P &lt; 0.001). After 10 months, the rate of symptoms in the oral immunotherapy group decreased to 8.3% (15,815 doses). In addition to dosing‐related symptoms, 437 other adverse events were reported; 96% were considered to be unrelated to dosing on the basis of the timing and types of symptoms. </p> <p><a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a> (N = 72) described 21 children (52.5%) who had symptoms at some stage of oral immunotherapy treatment. In eight children (20%) symptoms were very mild, and moderate‐to‐severe in 13 children. Eight children required treatment with antihistamines and corticosteroids and five children required epinephrine treatment. </p> <p><a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a> (N = 20) reported that all children who received oral immunotherapy experienced adverse events (n = 53 events) although none resulted from accidental exposure to egg. According to Sampson’s classification, where grade 1 is the mildest anaphylactic reaction and grade 5 is severe anaphylactic reaction with loss of consciousness (<a href="./references#CD010638-bbs2-0051" title="SampsonHA . Anaphylaxis and emergency treatment. Pediatrics2003;111:1601‐8. ">Sampson 2003</a>), three (5.6%) were grade 1, 10 (18.9%) were grade 2, 35 (66%) were grade 3, and five (9%) were grade 4. No children in the oral immunotherapy group had a grade 5 reaction, needed oral or intramuscular steroids or epinephrine, or required access emergency services. Eighty‐one per cent of adverse events occurred during administration of the first 6 mL, and 100% occurred with first administration of 20 mL hen's egg, which means that all children experienced some adverse events while increasing the oral immunotherapy dosage. The children in the oral immunotherapy group had relative risk of 4.96 (95% CI 3.30 to 7.45) for incurring an adverse event, but there were no significant differences in severity of reactions. No children discontinued treatment because of adverse events. Three children (30%) in the control group had a total of five adverse events because of accidental ingestion of trace amounts of egg. The severity grade was 3 or 4; no children required intramuscular epinephrine. </p> <p>In <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> (N = 20) 70% of children presented with mild‐to‐severe adverse events. No serious adverse events were reported. </p> <p>In <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> (N = 82), 45 children (90%) had dose‐related events including 13 who required epinephrine treatment. There were 1024 adverse events detected, corresponding to 7.6% of oral immunotherapy doses. The highest incidence of events occurred during the induction phase. The symptom distribution of adverse events were: vomiting (19.7%); lower respiratory tract involvement (18.8%); abdominal pain (15.7%); mouth itchiness (13.7%); urticaria (13.1%); rhinoconjunctivitis (7.7%); angioedema (6.7%); hoarseness (2.1%); diarrhoea (1.5%) atopic dermatitis flare (0.7%); and dysphagia (0.5%). Delayed adverse events represented a total of 4.3% of all reactions (3.8% gastro‐ intestinal plus 0.5% skin symptoms). The severity distribution of adverse events (as classified by Sampson's anaphylaxis grading, <a href="./references#CD010638-bbs2-0051" title="SampsonHA . Anaphylaxis and emergency treatment. Pediatrics2003;111:1601‐8. ">Sampson 2003</a>) was: grade 1 = 30%; grade 2 = 31.2%; grade 3 = 15.9%; and grade 4 = 22.9%. Grade 4 was experienced by 58% of children receiving oral immunotherapy, consisting of a mild cough/wheeze in 78% of occasions. One child experienced a grade 5 reaction during the induction phase, leading to discontinuation. Multisystem involvement represented a total of 11.5% of all dose‐related adverse events. Accidental adverse events occurred in five children (15.6%) in the control group, nevertheless no epinephrine or adrenaline was needed. There was a total of 1024 adverse events in the oral immunotherapy group and seven in the control group. </p> <p><a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> (N = 31) reported that adverse events occurred in three children during the desensitization procedure, one of whom discontinued oral immunotherapy. In the egg‐containing diet arm, one child had abdominal pain with urticaria after exercise, and another had rhinitis and/or asthma during a respiratory tract infection. One participant (5.9%) required epinephrine treatment. No adverse events were observed in the control group. </p> <p><a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> (N = 61) reported 145 allergic reactions as adverse events during oral immunotherapy in 70% (N = 21) of children, presented mainly in the escalation phase (70%, N = 21), followed by the build‐up phase (53%, N = 16) and reducing to 33% (N = 10) in the maintenance phase. Ninty‐eight per cent (98%) of children experienced mild symptoms and 2% had a moderate allergic reaction. In one child (0.04%) epinephrine treatment was needed due to a systemic reaction (rhinitis, urticaria, and mild respiratory distress). The protocol was modified for this child by reducing the oral immunotherapy dose by 50%. The most common adverse events were gastro‐intestinal (82%), oropharyngeal symptoms (21.5%), rhinitis (11.4%), respiratory distress (6.3%), and generalized urticaria (3.8%). Moreover, 7% of children (N = 2) withdrew from the study for non‐severe repeated allergic reactions (abdominal pain and vomiting). </p> <p><a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> (N = 29) reported that all children, except one in the oral immunotherapy group, experienced at least one adverse event during the course of treatment. There was no significant difference between the hydrolysed egg and placebo groups with respect to type of adverse events. </p> <p>In <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a> (N = 33), safety data during the first control randomized oral immunotherapy period, which was included in our analysis, was received from the authors following personal communication (<a href="./references#CD010638-bbs2-0037" title="Ibanez SandinMD . Safety data regarding first five month of ROIT1 [personal communication]. Email to: O Romantsik 12 February 2017. ">Ibanez Sandin MD 2017 [pers comm]</a>). Fifteen of 18 children presented with adverse events in the escalation phase (n = 40 adverse events). These included: oropharyngeal symptoms (n = 29); gastro‐intestinal symptoms (n = 17); cutaneous symptoms (n = 4); and rhinitis (n = 4). All adverse events were reported to be mild. At the beginning of the build‐up phase nine of 17 children presented with adverse events (n = 45 adverse events). All adverse events were mild, and the distribution among organ systems were similar to the build‐up phase: oropharyngeal symptoms (n = 37); gastro‐intestinal symptoms (n = 20); cutaneous symptoms (n = 10); rhinitis (n = 1); and asthma (n = 1). Five months after baseline in the maintenance phase, 45 mild adverse events were reported: oropharyngeal symptoms (n = 39); gastro‐intestinal symptoms (n = 10); cutaneous symptoms (n = 18); rhinitis (n = 4); and asthma (n = 2). Participants could present multiple symptoms in the same adverse event. </p> <p><a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a> (N = 36) reported that 17 of 18 children in the oral immunotherapy group experienced adverse events: vomiting (N = 4), diarrhoea (N = 5), urticaria or angioedema (N = 6), and respiratory symptoms including coughing and wheezing (N = 3). Of the three children with respiratory symptoms, one developed persistent asthma. Eight children had oral cavity itchiness and six children had mild abdominal pain, but no children required an epinephrine injection. A total of 32 mild‐to‐severe adverse events were reported. </p> </section> </section> <section id="CD010638-sec-0082"> <h4 class="title">Medication used due to adverse events</h4> <p><a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> mentioned that only one child received prednisone but without specifying the route, dose, or duration of treatment. In <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a> antihistamine therapy was administrated for 10 cases, steroids in nine cases, B2‐agonists in five cases, and epinephrine treatment in five cases. The administration route, dose, and duration of these medications were not reported. As mentioned previously, all children in <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> received cetirizine treatment orally (0.25 mg/kg/day) for the duration of the study, but no other medication was reported (<a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>). In <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>, information on medication used was reported for both groups, in association with oral immunotherapy dose for the experimental group and for traces of egg in the control group. Unfortunately, the number of cases in which antihistamine treatment was used was not clearly reported in the oral immunotherapy group. In the control group there were three cases requiring treatment. Nebulized epinephrine was used in two cases in the oral immunotherapy group and in two cases in the control group. There were three children in the oral immunotherapy group who needed B2‐agonists, and no cases were documented for steroid administration in the oral immunotherapy group. Additionally, there were two children in the control group who required oral steroid therapy. No information was provided for dose or duration. In <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> children with asthma on preventive treatment continued therapy during oral immunotherapy. Furthermore, according to the study protocol, antihistamines were indicated for adverse events during oral immunotherapy: rhinoconjunctivitis or skin symptoms, inhaled salbutamol for mild cough or wheeze, and epinephrine for moderate or severe anaphylaxis. There were 18 epinephrine injections in 13 cases, salbutamol was given on 159 occasions and antihistamines in 475, but without specifying the route, dose, or duration of the treatment. <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> reported three cases that required treatment: in one case intramuscular adrenaline, steroid, cetirizine, and inhaled salbutamol was used and oral immunotherapy was discontinued. In the second case oral antihistamine was used, and in the other case inhaled bronchodilators and steroids were used. There were no data available regarding dose or duration of treatment. <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> reported only one event where medication was needed ‐ the child required epinephrine treatment; subsequently, the oral immunotherapy protocol was reduced by 50%. No other treatments were reported. <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> did not report requirement for medication during oral immunotherapy treatment, despite the presence of adverse events. In <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a> all children received 10 mg of cetirizine daily during the build‐up phase and for half of the maintenance phase. The study authors did not report whether any medications were used to treat adverse events during the blinded phase of oral immunotherapy, but did report the use of antihistamines, corticosteroids, inhaled short‐acting B2‐broncodilatator and intramuscular adrenaline/epinephrine during the second, open phase of the study. <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a> reported use of antihistamines for recurrent adverse events, however there were no data available on how many times such a treatment was used during oral immunotherapy. The administration route, dose, and duration of these medications were not reported. </p> </section> <section id="CD010638-sec-0083"> <h4 class="title">Immunological changes</h4> <section id="CD010638-sec-0084"> <h5 class="title">Skin prick test (SPT)</h5> <p>Nine studies (403 children; 231 oral immunotherapy; 172 control/placebo) reported performing SPT at baseline (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012;</a><a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015;</a><a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013;</a><a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015;</a><a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016;</a><a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013;</a><a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>) and it was performed at the end of oral immunotherapy in seven studies (total number of children = 292; oral immunotherapy = 166; control/placebo = 126) (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012;</a><a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015;</a><a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013;</a><a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a><a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013;</a><a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). There were non‐significant differences between children in the oral immunotherapy and control groups before starting immunotherapy. A significant difference in SPT wheal size was found at the end of oral immunotherapy in all seven studies that performed the test (<a href="#CD010638-tbl-0002">Table 1</a>). Moreover, <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> showed that a decrease in wheal size from baseline to 22 months (P = 0.009) was correlated with sustained unresponsiveness at 24 months (P = 0.005). </p> <div class="table" id="CD010638-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Skin prick test to egg white (wheal size, mm)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study name</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Oral immunotherapy</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control/placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Oral immunotherapy versus control/placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pre‐treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Post‐treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pre‐treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Post‐treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value pre‐treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value post‐treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5</p> <p>(2.5 to 26.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.0</p> <p>(7.5 to 20.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.0</p> <p>(6.5 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.0</p> <p>(6.0 to 16.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> <p>(7.0 to 15.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0</p> <p>(4.0 to 13.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.25</p> <p>(5.5 to 15.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> <p>(5.5 to 15.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> <p>(3.0 to 11.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0</p> <p>(3.0 to 8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> <p>(3.0 to 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> <p>(0 to 13.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.74</p> <p>(4 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.68</p> <p>(3.0 to 16.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> <p>(2.5 to 7.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> <p>(1.0 to 5.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> <p>(1.0 to 7.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> <p>(1.0 to 8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> <p>(5.0 to 10.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> <p>(4.0 to 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.05</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD010638-sec-0085"> <h5 class="title">Serologic testing</h5> <p>Specific IgE (sIgE) levels at baseline and at the end of the oral immunotherapy protocol were investigated by using different laboratory methods in each study. However, there were no data available for sIgE levels at the end of the oral immunotherapy protocol in <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>. For sIgE determination <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>, <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>, <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>, <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>, <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>, <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> used the Thermo Immuno‐CAP system (Fisher Scientific); <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a> and <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a> used the Phadia CAP System fluorescence enzyme immunoassay (FEIA) (Phadia Diagnostics); <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> used the Realtest Reverse Enzyme Allergo Sorbent Test (REAST) (Lofarma) and an allergen micro array assay (Immuno Solid‐phase Allergen Chip ISAC; VBC Genomics Bioscience Research, Vienna, Austria) in accordance with the manufacturer’s recommendations. A panel of 104 allergens (inhalants and foods), that also contained the following five purified natural hen's egg allergens: ovomucoid (Gal d 1), ovalbumin (Gal d 2), ovotransferrin (Gal d 3), lysozyme (Gal d 4), and serum albumin (Gal d 5), was used. <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a> used CAP system for sIgE determination. Because of the differences in the upper limit of measurement it was impossible to combine data. </p> <p>Nevertheless, two studies reported a statistically significantly decreased levels of egg sIgE antibody after oral immunotherapy compared to control (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>). In <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a> (N = 20) the difference in the reduction of IgE between pre‐ and post‐oral immunotherapy was ‐14.4 kUA/L (range ‐27.6 to 0.1) in the oral immunotherapy group and 2 kUA/L (range ‐8.9 to ‐13.8) in the control group (P &lt; 0.001). Futhermore, the median reduction in sIgE levels from baseline to the end of oral immunotherapy protocol for egg oral immunotherapy group was not statistically significantly greater than that for control group (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> (N = 20) reported statistically significant reduction for sIgE before and after oral immunotherapy protocol for oral immunotherapy group: for ovomucoid (Gald1) by REAST (20.9 ± 45.6 versus 14.8 ± 30.7; P = 0.02), and for both ovomucoid (Gald1) (6.67 ± 8.36 versus 1.78 ± 1.74; P &lt; 0.01) and ovalbumin (Gald2) measured by ISAC method (2.92 ± 5.05 versus 0.74 ± 1.22; P &lt; 0.02), respectively. There were no differences in reduction of sIgE measured by REAST technique from baseline compared with the final point of the study in the control group. Interestingly, there was a statistically significant increase in ovomucoid (Gald1) measured using the ISAC method in the control group at the end of the study (5.32 ± 6.89 versus 7.81 ± 10.53; P &lt; 0.05). In <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> (N = 31), the egg‐specific IgE level after oral immunotherapy was 34.2 kUA/L in the intervention group and 38.9 kUA/L in the placebo group. Of note, follow‐up of these children showed that at 10 months, formerly active oral immunotherapy children who continued with an egg‐containing diet for the following six months had significantly lower sIgE levels compared to baseline (37.6 versus 12.2 kUA/L, P = 0.02). <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> (N = 61) reported a statistically significant decrease from baseline to the end of oral immunotherapy in both groups only for ovalbumin IgE (6.3 kUA/L (0.7 to 185) versus 2.2 kUA/L (0.3 to 192), P &lt; 0.001) and 2.2 kUA/L (0.7 to 43.5) versus 1.3 kUA/L (0.3 to 32.3), P = 0.01); no differences were seen for ovomucoid or egg white IgE. <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a> (N = 36) reported a statistically significant decrease in sIgE levels from baseline to the end of the study in the control group (median 36.4 versus 30.6 kUA/mL; P &lt; 0.05). It was not possible to extrapolate data for sIgE antibodies in <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>, <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>, or <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>. In <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> (N = 29) no statistically significant difference was observed regarding sIgE levels (change over time expressed as median (min‐max) ‐3.230 kUA/L (‐8.90 to 0.42); P = 0.29). </p> <p>Eight studies (total number of children = 337; oral immunotherapy = 189; control/placebo = 148) evaluated changes in egg‐specific IgG4 antibodies and all eight showed a statistically significant increase in the level of these antibodies after oral immunotherapy (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a> (N = 36) demonstrated a statistically significant increase of egg white‐specific IgG4 in the oral immunotherapy group after completing the oral immunotherapy protocol (median, 13 U/mL at baseline to 94 U/mL at the end of oral immunotherapy; P &lt; 0.01), whereas such a change was absent in the control group (median, 13 U/mL at baseline to 13 U/mL; P = 1.00). In <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> (N = 55) the median reduction of egg‐specific IgG4 by the end of oral immunotherapy for the oral immunotherapy group was significantly higher (median, 48.5 kU/L range ‐0.1 to 162.1; P &lt; 0.01) compared to the placebo group (there were no numerical data available for the placebo group). <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> (N = 31) reported a significant increase of the mean egg‐specific IgG4 levels by the end of oral immunotherapy in intervention group children (29.2 µg/mL versus 0.9 µg/mL, P = 0.001). In <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> (N = 61) there was an increase in median egg‐specific IgG4 observed from baseline to the end of oral immunotherapy in the oral immunotherapy group (0.4 mg/L (0.1 to 6.2) versus 4.4 mg/L (0.1 to 30), P = 0.0001). <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> (N = 29) reported a significant increase over time from baseline to the end of oral immunotherapy in specific IgG4 in the active group (expressed as change over time, median (range): for egg yolk IgG4 (0.10 mg/L, 0.00 to 1.71, P = 0.01) and for ovalbumin IgG4 (0.11 mg/L, ‐0.00 to 3.59, P = 0.04); there were no differences observed in the median change of IgG4 levels for egg white (0.07 mg/L, ‐0.31 to 2.54, P = 0.07) and for ovomucoid (0.00 mg/L, ‐0.56 to 1.04, P = 0.14). <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> (N = 20) found a statistically significant increase in the level of IgG4 only for ovalbumin (Gald2) at the end of oral immunotherapy (average, ± SD 2.6 mg/L (± 0.4) versus 2.95 mg/L (± 0.4); P = 0.02), but not for ovomucoid (Gald1) (average, ± SD 0.9 mg/L (± 0.7) versus q.8 mg/L (± 1.5). Data for the egg‐specific IgG4 levels were presented graphically in two studies and could not be extracted for analysis (<a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). </p> <p>In addition, six studies (281 children; oral immunotherapy = 161; control/placebo = 120) showed a statistically significant increase in IgG4 compared to the control group (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). In <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> (N = 31) egg‐specific IgG4 levels after oral immunotherapy were statistically significantly higher in the intervention group (29.2 µg/mL) than in the placebo group (1.5 µg/mL, P = 0.001). Follow‐up of these children showed that at 10 months, formerly active oral immunotherapy children who continued with egg‐containing diet for the following six months had significantly higher sIgG4 levels compared to baseline (32.4 versus 0.9 µg/mL, P = 0.001). Median sIgG4 levels in <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> (N = 61) were higher in the oral immunotherapy group by the end of oral immunotherapy than in the control group (4.4 mg/L (0.1 to 30) versus 0.4 mg/L (0.1 to 7.5); P = 0.001). <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> (N = 29) reported that a greater increase of egg‐specific IgG4 occurred in the oral immunotherapy group compared to placebo by the end of oral immunotherapy, however these data were not reported. It was not possible to extrapolate precise data for sIgG4 from <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>, <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a> and <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a> because data were reported graphically. </p> <p>Two studies reported a significant reduction in basophil activation test in the oral immunotherapy group compared to placebo at the end of treatment (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>) (84 children; oral immunotherapy group = 55; placebo group = 29): in <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> the differences in CD63 activation were statistically significant (0.01 μg/mL, P = 0.002; 0.1 μg/mL, P = 0.001). In <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> a significant decrease in percentage of CD203c+ cells (P = 0.04) occurred and there was a trend for a lower percentage of CD63+ cells (P = 0.07). </p> <p><a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> (N = 20) performed cytokines (IL‐4, IL‐5, IL‐6, IL‐10, IL‐12, IL‐13), interferon‐gamma and tumour necrosis factor‐alfa analysis and found a statistically significant increase of IL‐5 levels in the oral immunotherapy group at the end of treatment (mean, 19.00 ± 9.4 pg/mL; range = 5.00 to 32.00 versus 28.13 ± 14.7 pg/mL; range, 12.00 to 56.00; P = 0.03). </p> </section> </section> <section id="CD010638-sec-0086"> <h4 class="title">Quality of life and cost‐effectiveness</h4> <p>There were no data available regarding quality of life or cost‐effectiveness.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010638-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010638-sec-0087"></div> <section id="CD010638-sec-0088"> <h3 class="title" id="CD010638-sec-0088">Summary of main results</h3> <p>Egg oral immunotherapy appears to be an effective treatment option to induce desensitization in children with immunoglobulin E (IgE)‐mediated egg allergy, despite a difference in immunotherapy protocols. Nevertheless, oral immunotherapy is an alternative to the current therapeutic mainstay of an avoidance diet. Oral immunotherapy may have a positive effect on overall quality of life, including positive nutritional consequences and the potential avoidance of allergy related emergencies. </p> <p>Nearly half (45%) of children receiving oral immunotherapy were able to tolerate a full serving of egg compared to 10% of the control group (RR 4.25, 95% CI 2.77 to 6.53; RD 0.35, 95% CI 0.28 to 0.43; children = 439; studies = 10; I² = 22% for RR and I² = 86% for RD). Our GRADE assessment judged the quality of evidence to be low (<a href="./full#CD010638-tbl-0001">summary of findings Table for the main comparison</a>). We found that 82% of children receiving oral immunotherapy increased the amount of egg they could tolerate during the treatment period (RR 7.48, 95% CI 4.91 to 11.38; RD 0.73, 95% CI 0.67 to 0.80; children = 410; studies = 9; I² = 27% for RR and I² = 73% for RD). Our GRADE assessment judged the quality of evidence to be low (<a href="./full#CD010638-tbl-0001">summary of findings Table for the main comparison</a>). There were differences in the levels required for partial desensitization (defined as an increase in the threshold dose, not reaching one complete raw egg) achieved. Such differences may be due to different egg oral immunotherapy protocols used in the included trials. Moreover, it seems that regular consumption of uncooked egg and other egg‐containing food after stopping oral immunotherapy may be helpful to achieve sustained unresponsiveness to egg allergy. It was reported that 16 children who received oral immunotherapy achieved desensitization after six months of an egg‐containing diet, but after three months of an egg‐avoidance diet, only five children maintained tolerance to re‐introduction of eggs to their diet (<a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>). Of note, long‐term follow up of <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> reported that 50% of the children who were treated with egg oral immunotherapy in the original cohort achieved a sustained unresponsiveness by the fourth year of oral immunotherapy. </p> <p>There is a possibility that oral immunotherapy may modulate immunological response (<a href="./references#CD010638-bbs2-0039" title="JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Jones 2016</a>; <a href="./references#CD010638-bbs2-0059" title="WrightBL , KulisM , OrgelKA , BurksAW , DawsonP , HenningAK , et al. Component‐resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness. Allergy2016;71(11):1552‐60. ">Wright 2016</a>). Seven studies reported a significant reduction in wheal diameter on skin prick test after completion of oral immunotherapy (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012;</a><a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015;</a><a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013;</a><a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015;</a><a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013;</a><a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). Moreover, two studies showed a reduction in egg‐specific immunoglobulin E (sIgE) levels versus control (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>). Two further studies showed a reduction in egg sIgE levels versus baseline in children who received oral immunotherapy (<a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>). Of note, all eight studies that evaluated egg sIgG4 levels showed an increase in egg sIgG4 levels after oral immunotherapy (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012;</a><a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015;</a><a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015;</a><a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016;</a><a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013;</a><a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). Furthermore, two studies demonstrated a significant reduction in basophil activation in the oral immunotherapy group compared to placebo at the end of treatment (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012;</a><a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>). However, none of the immune parameters tested in the included studies were consistently predictive of the oral immunotherapy treatment outcomes (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012;</a><a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015;</a><a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013;</a><a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015;</a><a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016;</a><a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013;</a><a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). More data are needed to better understand the underlying mechanism that might be induced by oral immunotherapy. </p> <p>It is important to note that 75% of children in the intervention groups experienced at least one adverse event during oral immunotherapy (RR 8.35, 95% CI 5.31 to 13.12; RD 0.67, 95% CI 0.61 to 0.73; children = 439; studies = 10; I² = 29% for RR and I² = 82% for RD). Our GRADE assessment judged the quality of evidence to be low (<a href="./full#CD010638-tbl-0001">summary of findings Table for the main comparison</a>). Most symptoms were related to the build‐up phase in association with oral immunotherapy dosing. However, most symptoms were mild and self‐limiting. We found that 8.4% of children had a serious adverse event, requiring epinephrine/adrenaline administration (effect not estimable, our GRADE assessment judged the quality of evidence to be low, <a href="./full#CD010638-tbl-0001">summary of findings Table for the main comparison</a>). Because adverse events were defined differently among the included studies, it is difficult to comment on whether these were under‐ or over‐estimated. <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> reported 10 adverse events, but <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> reported 1024 adverse events. Surprisingly, only one study showed a high level of serious adverse events (<a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>): 13 children required epinephrine/adrenaline administration 18 times, and one grade 5 reaction occurred (according to the <a href="./references#CD010638-bbs2-0051" title="SampsonHA . Anaphylaxis and emergency treatment. Pediatrics2003;111:1601‐8. ">Sampson 2003</a> classification scheme). <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> reported that available treatments were insufficiently effective. The risks associated with administering oral immunotherapy need to be evaluated against the 'real life' risks of standard care, namely an avoidance diet, although it is difficult to accurately estimate the true rate of accidental allergic reactions. </p> <p>We found that reporting on different potential medications was poor. Although four included studies provided detailed information about antihistamine, steroid, epinephrine/adrenaline, and B2‐agonists administration in association with oral immunotherapy dose, and symptoms that occurred on those specific occasions, information on administration route, dose and duration of use was absent (<a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). Only <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> and <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a> administrated antihistamine treatment as a co‐intervention with oral immunotherapy. It was therefore difficult to assess whether oral immunotherapy‐induced adverse allergic reactions could be avoided. Likewise, because <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>, <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> and <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a> did not provide specific information regarding medications used for adverse events (antihistamines, steroids, epinephrine/adrenaline, B2‐agonists), it was difficult to assess the extent of oral immunotherapy‐induced adverse events. No study reported on drug administration route, dose and duration of such therapy. </p> <p><a href="./references#CD010638-bbs2-0054" title="SclarDA , LiebermanPL . Anaphylaxis: underdiagnosed, underreported, and undertreated. American Journal of Medicine2014;127(1 Suppl):S1‐5. ">Sclar 2014</a> reported that anaphylaxis is often underestimated. In a study of food‐related allergic reactions in children, the most common reason given for lack of epinephrine/adrenaline administration to children experiencing a severe adverse event was that the event was not recognized as severe (47.7% of cases in which epinephrine/adrenaline was not used) (<a href="./references#CD010638-bbs2-0033" title="FleischerDM , PerryTT , AtkinsD , WoodRA , BurksAW , JonesSM , et al. Allergic reactions to foods in preschool‐aged children in a prospective observational food allergy study. Pediatrics2012;130:e25‐32. ">Fleischer 2012</a>). </p> <p>Overall, the dropout rate, mainly due to adverse events, has been reported at 15% to 20% in oral immunotherapy trials (<a href="./references#CD010638-bbs2-0040" title="KhoriatyE , UmetsuDT . Oral immunotherapy for food allergy: towards a new horizon. Allergy, Asthma &amp; Immunology Research2013;5(1):3‐15. ">Khoriaty 2013</a>).The dropout rate data from <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>, <a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a>, <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>, <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>, <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a> agrees with the information reported previously in <a href="./references#CD010638-bbs2-0040" title="KhoriatyE , UmetsuDT . Oral immunotherapy for food allergy: towards a new horizon. Allergy, Asthma &amp; Immunology Research2013;5(1):3‐15. ">Khoriaty 2013</a>. However, the withdrawal rate in the other five studies (<a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>) was surprisingly low, with <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a> having no dropouts: it may be that participant collaboration is easier in a smaller study, perhaps because there is more medical attention. <a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a> did not discuss their high adherence rate within the study. <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> discussed the high adherence rate in their study, giving as the possible explanation a longer intervention period; the protocol took longer than the expected period (planned 181 days) with a mean of 219 days (range 178 to 287 days). The very gradual protocol that was adopted may encourage more safety and more parental collaboration as the percentage increment between doses was the same and there were no dose 'jumps' in the daily egg administrations for the entire period of desensitization. Moreover, co‐intervention with antihistamine was used in their study. More studies are needed to confirm or to disprove such a hypothesis. </p> </section> <section id="CD010638-sec-0089"> <h3 class="title" id="CD010638-sec-0089">Overall completeness and applicability of evidence</h3> <p>All included studies addressed the primary outcome of complete tolerance of one egg serving. The 10 included studies included only children and recruitment selection bias was possible. No included studies reported on adults. The study population characteristics suggest that the included studies may be generalizable to a larger population group. Oral immunotherapy appears to be effective both in young children and in later childhood. However, children aged less than three years were included in only <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016</a>, but the sample size was too small to draw any conclusions. More studies are needed in this age group. Nevertheless, one randomized controlled trial is registered in clinical.trials.gov that will also include adults (<a href="./references#CD010638-bbs2-0028" title="Cow's milk and hen's egg hyposensitization in adults. Ongoing studyApril 2015. ">NCT02083471</a>). Another factor that may influence the development of desensitization is the presence of anaphylaxis. Of the 10 included studies, two included children with a history of anaphylaxis (<a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>). Oral immunotherapy appeared to be effective regardless of anaphylaxis history. </p> <p>Oral immunotherapy both with and without an antihistamine co‐intervention was included in the review; this did not seem to affect the treatment effect. </p> <p>Of note, 45% of children achieved full tolerance after oral immunotherapy and could ingest a full serving of egg without adverse effect; these children were able to continue diets that included egg. However, concerns about compliance and interruption due to sickness should be addressed. </p> <p>We found that 82% of children could tolerate a partial serving of egg, reducing dietary limitations, and risk of serious adverse event. Adverse events are likely to be the most important factors to be considered when applying evidence to practice. The difference in reporting methods for symptoms during oral immunotherapy makes those symptoms complicated to quantify. As previously mentioned, there is a risk of both under‐ or over‐estimation. The need for parenteral epinephrine treatment could be a reflection of serious adverse events. Five studies reported the data of children in the oral immunotherapy group who needed epinephrine/adrenaline treatment (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a>; <a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). Requirement was as high as 26% of the oral immunotherapy group population (<a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>). On the other hand, frequent, milder symptoms during oral immunotherapy might influence participants’ quality of life and compliance. Inquiring about the study participants' acceptance of this therapy would be insightful. If applied to practice, physicians would have to cautiously consider, and discuss with the participant at length, whether the risks are acceptable; and to ensure good compliance of the children's parents or guardians. </p> <p>With one exception, all children in the included studies started oral immunotherapy during hospital admission, as day patients, or in a research centre. <a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a> started oral immunotherapy treatment at the child's home, but with medical personnel available to intervene if allergic reactions occurred. During the build‐up phase children were closely monitored during visits to the clinic or research centre, where close follow‐up and individualized guidance was provided. Whether these time and personnel commitments are feasible in practice could be a factor, and are dependent on the institution providing the oral immunotherapy. </p> <p>There was no information available regarding children's and their families quality of life during oral immunotherapy. It could be speculated that a high rate of even mild adverse events may negatively influence the everyday life of participants, and in the case of children, their caregivers. </p> </section> <section id="CD010638-sec-0090"> <h3 class="title" id="CD010638-sec-0090">Quality of the evidence</h3> <p>According to the GRADE approach described in Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010638-bbs2-0036" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>), the overall judgement of the quality of the body of evidence contributing to the results of the review is low. The reasons for downgrading evidence was the high likelihood of bias and imprecision of results (few events and a small number of participants). High likelihood of bias is suspected because of the methodological limitations in the studies, resulting in possible selection, performance, and detection bias. The confidence intervals were wide because of small sample sizes and variability in the estimated treatment effect. Four studies did not perform a sample size calculation and this could be a source of random error risk (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a>; <a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a>; <a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). The random error is closely related to imprecision. The results of smaller studies are subject to greater sampling variation and hence are less precise. Imprecision is reflected in the confidence interval around the intervention effect estimate from each study and in the weight given to the results of each study in the meta‐analysis (<a href="./references#CD010638-bbs2-0036" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). However, there was a consistently positive treatment effect of oral immunotherapy despite clinical heterogeneity, although a low I² value reflects non‐substantial statistical heterogeneity, and differences in oral immunotherapy protocols among studies. </p> <p>We did not include a sufficient number of studies to create a funnel plot to assess publication bias. Given few included studies, most of which detected statistically significant results, we could not rule out the presence of reporting bias. The strength of the evidence was that there was a consistently positive treatment effect, despite clinical heterogeneity in participant characteristics and oral immunotherapy protocols. Furthermore, we could not rule out the possibility of under‐or over‐reporting of adverse events during oral immunotherapy. </p> </section> <section id="CD010638-sec-0091"> <h3 class="title" id="CD010638-sec-0091">Potential biases in the review process</h3> <p>A strength of this review was the thorough search strategy, including several databases, conference papers, and trial registries, to minimize the possibility of missing studies. A possible source of bias relates to the exclusion of potentially relevant studies when requests to the authors for additional information went unanswered. These studies are listed in the <a href="./references#CD010638-sec-0111" title="">Characteristics of studies awaiting classification</a> tables. Moreover, some studies that fulfilled our criteria were excluded because they combined results for immunotherapy for two or more foods. For example, <a href="./references#CD010638-bbs2-0020" title="StadenU , Rolinck‐WerninghausC , BreweF , WahnU , NiggemannB , BeyerK . Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy2007;62(11):1261‐9. ">Staden 2007</a>, fulfilled the eligibility criteria but results for both egg and milk immunotherapy were combined in the published article and we were unable to split the data to focus only on egg allergy. It is possible that the inclusion of such data could have altered the results of the meta‐analysis. The ongoing studies (<a href="./references#CD010638-bbs2-0028" title="Cow's milk and hen's egg hyposensitization in adults. Ongoing studyApril 2015. ">NCT02083471</a>; <a href="./references#CD010638-bbs2-0027" title="Oral desensitization to egg with subsequent induction of sustained unresponsiveness for egg‐allergic children using baked egg or egg oral immunotherapy. Ongoing studyJuly 2013. ">NCT01846208</a>) emphasize the need for frequent updates of this review as oral immunotherapy for egg allergy continues to be a topic of active research. Ongoing and future studies could potentially affect our conclusions. </p> </section> <section id="CD010638-sec-0092"> <h3 class="title" id="CD010638-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, this is the only systematic review on immunotherapy specifically for egg allergy. The findings of our review are in agreement with a systematic review and meta‐analysis on food allergies that included evaluation of egg oral immunotherapy as a subgroup (<a href="./references#CD010638-bbs2-0045" title="NurmatovU , DhamiS , ArasiS , PajnoGB , Fernandez‐RivasM , MuraroA , et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy2017;72(8):1133‐47. [DOI: 10.1111/all.13124] ">Nurmatov 2017</a>). </p> <p><a href="./references#CD010638-bbs2-0045" title="NurmatovU , DhamiS , ArasiS , PajnoGB , Fernandez‐RivasM , MuraroA , et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy2017;72(8):1133‐47. [DOI: 10.1111/all.13124] ">Nurmatov 2017</a> included nine studies in the egg oral immunotherapy subgroup (<a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012;</a><a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015;</a><a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013;</a><a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015;</a><a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a><a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013;</a><a href="./references#CD010638-bbs2-0015" title="MorissetM , Moneret‐VautrinDA , GuenardL , CunyJM , FrentzP , HatahetR , et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow's milk allergy and 90 children with egg allergy. European Annals of Allergy and Clinical Immunology2007;39(1):12‐9. ">Morisset 2007;</a><a href="./references#CD010638-bbs2-0017" title="PatriarcaG , SchiavinoD , NuceraE , SchincoG , MilaniA , GasbarriniGB . Food allergy in children: results of a standardized protocol for oral desensitization. Hepatogastroenterology1998;45(19):52‐8. ">Patriarca 1998;</a><a href="./references#CD010638-bbs2-0020" title="StadenU , Rolinck‐WerninghausC , BreweF , WahnU , NiggemannB , BeyerK . Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy2007;62(11):1261‐9. ">Staden 2007</a>). <a href="./references#CD010638-bbs2-0045" title="NurmatovU , DhamiS , ArasiS , PajnoGB , Fernandez‐RivasM , MuraroA , et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy2017;72(8):1133‐47. [DOI: 10.1111/all.13124] ">Nurmatov 2017</a> excluded <a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>, and did not include three studies included in this review (<a href="./references#CD010638-bbs2-0001" title="AkashiM , YasudoH , NaritaM , NomuraI , AkasawaA , EbisawaM , et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatrics International2017;59(5):534‐9. ">Akashi 2017</a>; <a href="./references#CD010638-bbs2-0007" title="GiaviS , VissersYM , MuraroA , LauenerR , KonstantinopoulosAP , MercenierA . Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. European Journal of Allergy and Clinical Immunology2016;71(11):1575‐84. ">Giavi 2016;</a><a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a>). This was probably due to the last search date in <a href="./references#CD010638-bbs2-0045" title="NurmatovU , DhamiS , ArasiS , PajnoGB , Fernandez‐RivasM , MuraroA , et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy2017;72(8):1133‐47. [DOI: 10.1111/all.13124] ">Nurmatov 2017</a>, which was 31 March 2016. We did not include <a href="./references#CD010638-bbs2-0015" title="MorissetM , Moneret‐VautrinDA , GuenardL , CunyJM , FrentzP , HatahetR , et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow's milk allergy and 90 children with egg allergy. European Annals of Allergy and Clinical Immunology2007;39(1):12‐9. ">Morisset 2007</a>, <a href="./references#CD010638-bbs2-0017" title="PatriarcaG , SchiavinoD , NuceraE , SchincoG , MilaniA , GasbarriniGB . Food allergy in children: results of a standardized protocol for oral desensitization. Hepatogastroenterology1998;45(19):52‐8. ">Patriarca 1998</a> and <a href="./references#CD010638-bbs2-0020" title="StadenU , Rolinck‐WerninghausC , BreweF , WahnU , NiggemannB , BeyerK . Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy2007;62(11):1261‐9. ">Staden 2007</a> because these studies combined results for egg and milk allergy. </p> <p><a href="./references#CD010638-bbs2-0045" title="NurmatovU , DhamiS , ArasiS , PajnoGB , Fernandez‐RivasM , MuraroA , et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy2017;72(8):1133‐47. [DOI: 10.1111/all.13124] ">Nurmatov 2017</a> found that oral immunotherapy substantially reduced the risk for egg allergy (RR hen's egg = 0.22, 95% CI 0.11 to 0.45). Of note, safety data remain a challenge. <a href="./references#CD010638-bbs2-0045" title="NurmatovU , DhamiS , ArasiS , PajnoGB , Fernandez‐RivasM , MuraroA , et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy2017;72(8):1133‐47. [DOI: 10.1111/all.13124] ">Nurmatov 2017</a> pooled safety data for three food allergies (cow's milk, egg, and peanut allergies), making comparisons difficult. </p> <p>We included 10 studies that reported significant numbers of adverse events during oral immunotherapy (<a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>), which was not included in <a href="./references#CD010638-bbs2-0045" title="NurmatovU , DhamiS , ArasiS , PajnoGB , Fernandez‐RivasM , MuraroA , et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy2017;72(8):1133‐47. [DOI: 10.1111/all.13124] ">Nurmatov 2017</a>. Another difference regarding safety between our review and <a href="./references#CD010638-bbs2-0045" title="NurmatovU , DhamiS , ArasiS , PajnoGB , Fernandez‐RivasM , MuraroA , et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy2017;72(8):1133‐47. [DOI: 10.1111/all.13124] ">Nurmatov 2017</a> was documentation of serious adverse events of oral immunotherapy treatment, requiring epinephrine/adrenaline administration. This was not reported in <a href="./references#CD010638-bbs2-0045" title="NurmatovU , DhamiS , ArasiS , PajnoGB , Fernandez‐RivasM , MuraroA , et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy2017;72(8):1133‐47. [DOI: 10.1111/all.13124] ">Nurmatov 2017</a>. Moreover, medication used for the treatment of adverse events was not reported in <a href="./references#CD010638-bbs2-0045" title="NurmatovU , DhamiS , ArasiS , PajnoGB , Fernandez‐RivasM , MuraroA , et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy2017;72(8):1133‐47. [DOI: 10.1111/all.13124] ">Nurmatov 2017</a>. </p> <p>An outcome in both our review and in <a href="./references#CD010638-bbs2-0045" title="NurmatovU , DhamiS , ArasiS , PajnoGB , Fernandez‐RivasM , MuraroA , et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy2017;72(8):1133‐47. [DOI: 10.1111/all.13124] ">Nurmatov 2017</a> was assessment of changes in disease‐specific quality of life using a validated instrument. Results were similar in both reviews: both reported lack of quality of life data. </p> <p>We agree with conclusions made by the authors of <a href="./references#CD010638-bbs2-0045" title="NurmatovU , DhamiS , ArasiS , PajnoGB , Fernandez‐RivasM , MuraroA , et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy2017;72(8):1133‐47. [DOI: 10.1111/all.13124] ">Nurmatov 2017</a> that oral immunotherapy may be effective in increasing desensitization in participants with IgE‐mediated egg allergy, and that oral immunotherapy is associated with a modest increased risk in serious systemic adverse events and a substantial increase in mild‐to‐severe adverse events. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010638-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/urn:x-wiley:14651858:media:CD010638:CD010638-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_t/tCD010638-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010638-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010638-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/urn:x-wiley:14651858:media:CD010638:CD010638-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_t/tCD010638-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010638-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010638-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/urn:x-wiley:14651858:media:CD010638:CD010638-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_t/tCD010638-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010638-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010638-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/urn:x-wiley:14651858:media:CD010638:CD010638-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_t/tCD010638-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral and sublingual immunotherapy versus no therapy for egg allergy, Outcome 1 Increase in the amount of egg that can be tolerated." data-id="CD010638-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oral and sublingual immunotherapy versus no therapy for egg allergy, Outcome 1 Increase in the amount of egg that can be tolerated. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/references#CD010638-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010638-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/urn:x-wiley:14651858:media:CD010638:CD010638-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_t/tCD010638-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral and sublingual immunotherapy versus no therapy for egg allergy, Outcome 2 Complete recovery." data-id="CD010638-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oral and sublingual immunotherapy versus no therapy for egg allergy, Outcome 2 Complete recovery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/references#CD010638-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010638-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/urn:x-wiley:14651858:media:CD010638:CD010638-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_t/tCD010638-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral and sublingual immunotherapy versus no therapy for egg allergy, Outcome 3 Number of participants with serious adverse events." data-id="CD010638-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oral and sublingual immunotherapy versus no therapy for egg allergy, Outcome 3 Number of participants with serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/references#CD010638-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010638-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/urn:x-wiley:14651858:media:CD010638:CD010638-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_t/tCD010638-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral and sublingual immunotherapy versus no therapy for egg allergy, Outcome 4 Number of participants with mild‐to‐severe adverse events." data-id="CD010638-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oral and sublingual immunotherapy versus no therapy for egg allergy, Outcome 4 Number of participants with mild‐to‐severe adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/references#CD010638-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/media/CDSR/CD010638/image_n/nCD010638-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010638-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral and sublingual immunotherapy versus no therapy for egg allergy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral and sublingual immunotherapy versus no therapy for egg allergy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> children with egg allergy </p> <p><b>Setting:</b> hospitals <br/> <b>Intervention:</b> oral and sublingual immunotherapy for egg allergy. (Each study used a different oral immunotherapy protocol) </p> <p><b>Comparison:</b> placebo or egg‐free diet. (Three studies used placebo and seven studies used an egg avoidance diet as controls) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral immunotherapy versus no therapy for egg allergy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Increase in the amount of egg that could be tolerated</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 7.48</b> <br/> (4.91 to 11.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>410<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>82% of children in the oral immunotherapy group could ingest a partial serving of egg (1 g to 7.5 g) compared to 10% of the control group. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>763 per 1000</b><br/> (501 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complete recovery</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 4.25</b> <br/> (2.77 to 6.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>439<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>45% of children receiving oral immunotherapy were able to tolerate a full serving of egg compared to 10% of the control group. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>425 per 1000</b><br/> (277 to 653) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Numbers of children with serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All 10 trials reported numbers of children with serious adverse events (SAEs): SAEs requiring epinephrine/adrenaline occurred in 21/249 (8.4%) of children in the oral immunotherapy group and none in the control group. </p> <p>Because adverse events were classified differently among the studies, it is difficult to comment on whether they were under‐ or over‐estimated. Surprisingly, only one study showed a high level of SAEs (<a href="./references#CD010638-bbs2-0010" title="Vazquez‐OrtizM , AlvaroM , PiquerM , DominguezO , MachinenaA , Martın‐MateosMA , et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg‐allergic children. Clinical and Experimental Allergy2014;44(1):130‐41. ">Vazquez‐Ortiz 2014</a>): 13 children required epinephrine/adrenaline administration 18 times, and one grade 5 reaction occurred. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of children with mild‐to‐severe adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 8.35</b> <br/> (5.31 to 13.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>439<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mild‐to‐severe adverse events were frequent; 75% of children presented mild‐to‐severe adverse events during oral immunotherapy treatment versus 6.8% of children in the control group. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>568 per 1000</b><br/> (361 to 892) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the risk of the control arm</p> <p><sup>1</sup> Downgraded one level because of risk of bias: all studies were assessed at high or unclear risk of bias in at least one domain.<br/> <sup>2</sup> Downgraded one level because of imprecision: few events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral and sublingual immunotherapy versus no therapy for egg allergy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010638-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Skin prick test to egg white (wheal size, mm)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study name</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Oral immunotherapy</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Control/placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Oral immunotherapy versus control/placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pre‐treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Post‐treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pre‐treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Post‐treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value pre‐treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value post‐treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0002" title="BurksAW , JonesSM , WoodRA , FleischerDM , SichererSH , LindbladRW , et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine2012;367(3):233‐43. JonesSM , BurksAW , KeetC , VickeryBP , ScurlockAM , WoodRA , et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. Journal of Allergy and Clinical Immunology2016;137(4):1117‐27. ">Burks 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5</p> <p>(2.5 to 26.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.0</p> <p>(7.5 to 20.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0003" title="CaminitiL , PajnoGB , CrisafulliG , ChieraF , ColluraM , PanasciG , et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with postdesensitization follow‐up. Journal of Allergy and Clinical Immunology: In Practice2015;3(4):532‐9. ">Caminiti 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.0</p> <p>(6.5 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.0</p> <p>(6.0 to 16.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0004" title="Dello IaconoI , TripodiS , CalvaniM , PanettaV , VergaMC , Miceli SopoS . Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: A randomized controlled trial. Pediatric Allergy and Immunology2013;24(1):66‐74. ">Dello Iacono 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> <p>(7.0 to 15.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0</p> <p>(4.0 to 13.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.25</p> <p>(5.5 to 15.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> <p>(5.5 to 15.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0005" title="EscuderoC , Rodrıguez del RıoP , Sánchez‐GarciaS , Pérez‐RangelI , Pérez‐FarinósN , Garcia‐FernándezC , et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clinical and Experimental Allergy2015;45(12):1833‐43. ">Escudero 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> <p>(3.0 to 11.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0</p> <p>(3.0 to 8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> <p>(3.0 to 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> <p>(0 to 13.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0006" title="Fuentes‐AparicioV , Alvarez‐PereaA , InfanteS , ZapateroL , D’OleoA , Alonso‐LebreroE . Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergologia et Immunopathologia2013;41(3):143‐50. ">Fuentes‐Aparicio 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.74</p> <p>(4 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.68</p> <p>(3.0 to 16.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0008" title="MeglioP , GiampietroPG , CarelloR , GabrieleI , AvitabileS , GalliE . Oral food desensitization in children with IgE‐mediated hen’s egg allergy:a new protocol with raw hen’s egg. Pediatric Allergy and Immunology2013;24(1):75‐83. ">Meglio 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> <p>(2.5 to 7.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> <p>(1.0 to 5.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> <p>(1.0 to 7.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> <p>(1.0 to 8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010638-bbs2-0009" title="Pérez‐RangelI , Rodríguez Del RíoP , EscuderoC , Sánchez‐GarcíaS , Sánchez‐HernándezJJ , IbáñezMD . Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial. Annals of Allergy, Asthma &amp; Immunology2017;118(3):356‐64. ">Pérez‐Rangel 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> <p>(5.0 to 10.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> <p>(4.0 to 12.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.05</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Skin prick test to egg white (wheal size, mm)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/full#CD010638-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010638-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral and sublingual immunotherapy versus no therapy for egg allergy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Increase in the amount of egg that can be tolerated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.48 [4.91, 11.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Complete recovery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.25 [2.77, 6.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of participants with serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants with mild‐to‐severe adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.35 [5.31, 13.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral and sublingual immunotherapy versus no therapy for egg allergy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010638.pub3/references#CD010638-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010638.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010638-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010638-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD010638-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD010638-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD010638-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD010638-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010638-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010638\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010638\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010638\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010638\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010638\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010638.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010638.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010638.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010638.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010638.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719711024"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010638.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719711028"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010638.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918def6bc9e29371',t:'MTc0MDcxOTcxMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 